<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta http-equiv="refresh" content="86400">
    <style>
        body {
            font-family: Arial, sans-serif;
            line-height: 1.6;
            max-width: 1200px;
            margin: 0 auto;
            padding: 20px;
            background-color: #f5f5f5;
        }
        h1 {
            color: #333;
            text-align: center;
            margin-bottom: 30px;
        }
        .news-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(350px, 1fr));
            gap: 20px;
        }
        .news-card {
            background-color: white;
            border-radius: 8px;
            box-shadow: 0 2px 5px rgba(0,0,0,0.1);
            padding: 20px;
            transition: transform 0.2s ease;
        }
        .news-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
        }
        .news-title {
            font-size: 18px;
            margin-top: 0;
        }
        .news-source {
            color: #666;
            font-size: 14px;
            margin-bottom: 10px;
        }
        .company-tag {
            display: inline-block;
            background-color: #e0f7fa;
            color: #006064;
            padding: 3px 8px;
            border-radius: 4px;
            font-size: 12px;
            font-weight: bold;
        }
        .news-date {
            color: #888;
            font-size: 12px;
            margin-top: 10px;
        }
        .timestamp {
            text-align: left;
            color: #000000;
            font-size: 24px;
            margin-top: 0px;
        }
        a {
            color: #0066cc;
            text-decoration: none;
        }
        a:hover {
            text-decoration: underline;
        }
        .header {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-bottom: 20px;
        }
        /* Image thumbnail styles */
        .news-image {
            margin-bottom: 15px;
            max-height: 180px;
            overflow: hidden;
            border-radius: 6px;
        }
        .news-image img {
            width: 100%;
            height: 180px;
            object-fit: cover;
            display: block;
            transition: transform 0.3s ease;
        }
        .news-card:hover .news-image img {
            transform: scale(1.05);
        }
        
        /* Chatbot styles */
        .chatbot-container {
            position: fixed;
            top: 20px; /* Changed from bottom to top */
            right: 20px;
            width: 350px;
            height: calc(100vh - 40px); /* Changed to take up almost full viewport height */
            background-color: white;
            border-radius: 10px;
            box-shadow: 0 5px 25px rgba(0,0,0,0.2);
            display: flex;
            flex-direction: column;
            z-index: 1000;
            transition: transform 0.3s ease, opacity 0.3s ease;
            transform: translateX(110%); /* Changed from translateY to translateX */
            opacity: 0;
            overflow: hidden; /* Added to ensure no overflow */
        }
        
        .chatbot-container.active {
            transform: translateX(0); /* Changed from translateY to translateX */
            opacity: 1;
        }
        
        .chatbot-header {
            background-color: #0066cc;
            color: white;
            padding: 15px;
            border-radius: 10px 10px 0 0;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }
        
        .chatbot-title {
            font-weight: bold;
            margin: 0;
        }
        
        .chatbot-messages {
            flex: 1;
            padding: 15px;
            overflow-y: auto;
            display: flex;
            flex-direction: column;
            max-height: calc(100vh - 140px); /* Added to ensure scrolling works properly */
        }
        
        .message {
            margin-bottom: 10px;
            max-width: 80%;
            padding: 10px 15px;
            border-radius: 18px;
            line-height: 1.4;
        }
        
        .user-message {
            align-self: flex-end;
            background-color: #0066cc;
            color: white;
        }
        
        .bot-message {
            align-self: flex-start;
            background-color: #f1f1f1;
        }
        
        .chatbot-input {
            display: flex;
            padding: 10px;
            border-top: 1px solid #e0e0e0;
        }
        
        .chatbot-input input {
            flex: 1;
            padding: 10px 15px;
            border: 1px solid #ddd;
            border-radius: 20px;
            outline: none;
        }
        
        .chatbot-input button {
            background-color: #0066cc;
            color: white;
            border: none;
            border-radius: 20px;
            padding: 10px 15px;
            margin-left: 10px;
            cursor: pointer;
        }
        
        .chat-toggle-button {
            position: fixed;
            bottom: 20px;
            right: 20px;
            width: 60px;
            height: 60px;
            background-color: #0066cc;
            color: white;
            border: none;
            border-radius: 50%;
            display: none; /* Changed from flex to none to hide initially */
            justify-content: center;
            align-items: center;
            font-size: 24px;
            cursor: pointer;
            box-shadow: 0 4px 8px rgba(0,0,0,0.2);
            z-index: 1001;
            opacity: 1;
            visibility: visible;
        }
        
        /* Adding a pulsing animation to make the chat button more noticeable */
        @keyframes pulse {
            0% { transform: scale(1); box-shadow: 0 4px 8px rgba(0,0,0,0.2); }
            50% { transform: scale(1.05); box-shadow: 0 8px 16px rgba(0,0,0,0.3); }
            100% { transform: scale(1); box-shadow: 0 4px 8px rgba(0,0,0,0.2); }
        }
        
        .chat-toggle-button {
            animation: pulse 2s infinite;
        }
        
        .chat-toggle-button:hover {
            background-color: #0055bb;
        }

        .source-citation {
            font-size: 12px;
            color: #666;
            margin-top: 5px;
            font-style: italic;
        }
    </style>
</head>
<body>
    <div class="news-grid">

    <div class="news-card">
        <span class="company-tag">Unaliwear</span>
        
        <h3 class="news-title"><a href="https://www.forbes.com/health/medical-alert-systems/unaliwear-review/" target="_blank">UnaliWear Medical Alert Watch Review (2025) - Forbes Health</a></h3>
        <div class="news-source">Forbes</div>
        <p>UnaliWear offers two monitoring subscription options for the Kanega Watch: the annual plan and the monthly plan. For the annual plan, users pay for device setup and 12 months of service upfront.</p>
        <div class="news-date">2024-02-15</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Unaliwear</span>
        
        <h3 class="news-title"><a href="https://www.consumeraffairs.com/medical-alert-systems/unaliwear-kanega-watch.html" target="_blank">UnaliWear Kanega Watch Reviews: Written By Customers in 2025</a></h3>
        <div class="news-source">ConsumerAffairs</div>
        <p>The UnaliWear Kanega Watch is a more discreet alternative to traditional medical alert devices. The watch weighs 49 grams (about 1.7 ounces). It&#x27;s 1.6 inches in diameter and 0.5 inches thick. It ...</p>
        <div class="news-date">2025-06-05</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">BrainCheck</span>
        
        <h3 class="news-title"><a href="https://markets.businessinsider.com/news/stocks/new-and-real-world-research-supports-braincheck-s-cognitive-assessment-and-care-planning-solutions-1032812763" target="_blank">New and Real-World Research Supports BrainCheck&#x27;s Cognitive Assessment ...</a></h3>
        <div class="news-source">Business Insider</div>
        <p>Clinicians and patients report high levels of satisfaction with BrainCheck&#x27;s standard battery, Assessâ„¢ and care planning tool, Planâ„¢ Studies confirm Assess can effectively determine severity ...</p>
        <div class="news-date">2023-11-13</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">BrainCheck</span>
        
        <h3 class="news-title"><a href="https://finance.yahoo.com/news/braincheck-expands-first-end-end-130000828.html" target="_blank">BrainCheck Expands First End-to-End Solution for Cognitive Care</a></h3>
        <div class="news-source">Yahoo Finance</div>
        <p>BrainCheck, Inc. launched the next generation of its comprehensive platform and unveiled its latest innovation, BrainCheckÂ® Screenâ„¢, at the Clinical Trials on Alzheimer&#x27;s Disease (CTAD ...</p>
        <div class="news-date">2023-10-24</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Dermala</span>
        
        <h3 class="news-title"><a href="https://markets.businessinsider.com/news/stocks/dermala-a-consumer-dermatology-company-announces-issuance-of-the-second-u-s-patent-covering-the-use-of-novel-human-microbiome-technology-for-treating-acne-vulgaris-1030899083" target="_blank">DERMALA, A Consumer Dermatology Company, Announces Issuance of the ...</a></h3>
        <div class="news-source">Business Insider</div>
        <p>DERMALA developed a novel technology for enhanced targeted delivery of human microbiome-derived postbiotic metabolites into specific layers of the skin.</p>
        <div class="news-date">2021-10-26</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Dermala</span>
        
        <h3 class="news-title"><a href="https://markets.businessinsider.com/news/stocks/dermala-ceo-and-founder-invited-as-speaker-and-panelist-to-two-upcoming-industry-conferences-1031304308" target="_blank">DERMALA CEO AND FOUNDER INVITED AS SPEAKER AND ... - Markets Insider</a></h3>
        <div class="news-source">Business Insider</div>
        <p>DERMALA, Inc. is a San Diego -based company leveraging a scientific understanding of the human microbiome and data analytics to develop novel personalized treatments for chronic skin conditions.</p>
        <div class="news-date">2022-03-24</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Oralucent</span>
        
        <h3 class="news-title">No news</h3>
        <div class="news-source"></div>
        <p></p>
        
    </div>
    
    <div class="news-card">
        <span class="company-tag">Flowly</span>
        
        <h3 class="news-title"><a href="https://www.fiercehealthcare.com/digital-health/relaxation-app-vr-startup-flowly-rolls-out-program-providers" target="_blank">Relaxation app startup Flowly rolls out program for providers</a></h3>
        <div class="news-source">Fierce Healthcare</div>
        <p>Flowly, an app for autonomic nervous system regulation, has launched a program for providers, the company has shared exclusively with Fierce Healthcare. | Through the program, ...</p>
        <div class="news-date">2023-03-13</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Flowly</span>
        
        <h3 class="news-title"><a href="https://www.androidheadlines.com/2014/02/sponsored-app-review-flowly.html" target="_blank">Sponsored App Review: Flowly - Android Headlines</a></h3>
        <div class="news-source">Android</div>
        <p>Description: Flowly (which some of you might have known as Android Hub) is an Android app that&#x27;s quite literally, all about Android. It&#x27;s essentially a self-contained RSS reader that&#x27;s full ...</p>
        <div class="news-date">2014-02-19</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Rosy Wellness</span>
        
        <h3 class="news-title"><a href="https://finance.yahoo.com/news/dar-bioscience-rosy-wellness-announce-120000637.html" target="_blank">DarÃ© Bioscience and Rosy Wellness Announce Strategic Collaboration to ...</a></h3>
        <div class="news-source">Yahoo Finance</div>
        <p>Collaboration will leverage Rosy Wellness&#x27; extensive reach and community of over 250,000 women Rosy Wellness is a multi-award winning app recommended by 8,000+ healthcare professionals DarÃ© ...</p>
        <div class="news-date">2025-06-04</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Rosy Wellness</span>
        
        <h3 class="news-title"><a href="https://medcitynews.com/tag/rosy-wellness/" target="_blank">rosy wellness Coverage - MedCity News</a></h3>
        <div class="news-source">MedCity News</div>
        <p>In recent years, providers have been increasingly conducting tech pilots to see which solutions can best improve their clinical and operation success. During a panel at MedCity News&#x27; INVEST ...</p>
        <div class="news-date">2024-09-19</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">De Oro Devices</span>
        
        <h3 class="news-title"><a href="https://finance.yahoo.com/news/oro-devices-names-cori-lathan-220500791.html" target="_blank">De Oro Devices Names Cori Lathan, PhD, as New CEO - Yahoo Finance</a></h3>
        <div class="news-source">Yahoo Finance</div>
        <p>Dr. Lathan joins De Oro Devices from her previous role as CEO at AnthroTronix, where she successfully invented, developed, and commercialized medical technology for over 20 years before leading ...</p>
        <div class="news-date">2024-01-18</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">De Oro Devices</span>
        
        <h3 class="news-title"><a href="https://abc30.com/parkinsons-disease-nexstride-device-de-oro-devices-clovis-veteran-able-to-walk/12728394/" target="_blank">New device helps Clovis veteran with Parkinson&#x27;s walk again</a></h3>
        <div class="news-source">ABC30 Action News</div>
        <p>The simple act of walking can be challenging for those living with Parkinson&#x27;s disease, which affects movement. However, a Clovis veteran is now on the move with the help of a newly-invented device.</p>
        <div class="news-date">2023-01-25</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Partum Health</span>
        
        <h3 class="news-title"><a href="https://medcitynews.com/2023/06/maternal-healthcare-postpartum-birth-fertility/" target="_blank">INVEST Pitch Perfect Spotlight: How Partum Health Is Working To ...</a></h3>
        <div class="news-source">MedCity News</div>
        <p>Partum Health, a maternal health startup, recently won the consumer/employer track of the MedCity News INVEST Pitch Perfect contest. The direct-to-consumer company supports families during ...</p>
        <div class="news-date">2023-06-03</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Partum Health</span>
        
        <h3 class="news-title"><a href="https://finance.yahoo.com/news/partum-health-expands-dallas-mission-124100615.html" target="_blank">Partum Health Expands to Dallas, On A Mission to Elevate Maternal Care ...</a></h3>
        <div class="news-source">Yahoo Finance</div>
        <p>Partum Health, the Chicago-based maternal health startup that offers direct-to-consumer interdisciplinary pregnancy and postpartum care, is expanding to Dallas, the brand&#x27;s third market.</p>
        <div class="news-date">2024-08-21</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Fort Health</span>
        
        <h3 class="news-title"><a href="https://www.victoriaadvocate.com/fort-health-partners-with-colleva-to-train-its-therapists-with-ai-patient-avatars-for-role/article_1aabcc2c-daf6-58b1-a558-b960053187f5.html" target="_blank">Fort Health Partners with Colleva to Train its Therapists with AI ...</a></h3>
        <div class="news-source">The Victoria Advocate</div>
        <p>Agentic AI Custom Training Scenarios Result in 83% of Clinicians Feeling More Prepared and 95% Able to Apply What They Have Learned &quot;AI-powered avatar simulations are revolutionizing therapist ...</p>
        <div class="news-date">2025-03-18</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Fort Health</span>
        
        <h3 class="news-title"><a href="https://www.msn.com/en-us/health/other/at-fort-health-my-teen-finally-found-a-therapist-he-doesn-t-hate/ar-AA1uiCeX" target="_blank">At Fort Health, My Teen Finally Found a Therapist He Doesn&#x27;t Hate</a></h3>
        <div class="news-source">MSN</div>
        <p>My teen has tried three different online therapy services, but Fort Health was the best experience by far. Read my full review to find out why its personalized experience, user-friendly sign-up ...</p>
        <div class="news-date">2024-11-18</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">RubyWell</span>
        
        <h3 class="news-title">No news</h3>
        <div class="news-source"></div>
        <p></p>
        
    </div>
    
    <div class="news-card">
        <span class="company-tag">Atlantic Sea Farms</span>
        
        <h3 class="news-title"><a href="https://www.pbs.org/video/atlantic-sea-farms-b1pe1x/" target="_blank">tasteMAKERS | Atlantic Sea Farms | Season 2 | Episode 201 - PBS</a></h3>
        <div class="news-source">PBS</div>
        <p>Atlantic Sea Farms. Season 2 Episode 201 | 26m 4s Video has Closed Captions | CC. Atlantic Sea Farms partners with lobstermen up and down the rocky coast of Maine to farm kelp in the region&#x27;s ...</p>
        <div class="news-date">2020-01-04</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Atlantic Sea Farms</span>
        
        <h3 class="news-title"><a href="https://www.pressherald.com/2022/10/03/maine-seaweed-company-looks-to-continue-expansion-with-new-investment-deal-with-top-chef-judge/" target="_blank">Maine seaweed company bids for more growth, signs deal with business ...</a></h3>
        <div class="news-source">Portland Press Herald</div>
        <p>Atlantic Sea Farms filed paperwork for the private financing with the Securities and Exchange Commission on Sept. 23. The funding drive comes a year after Atlantic raised $3.1 million in venture ...</p>
        <div class="news-date">2022-10-03</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">VidaFuel</span>
        
        <h3 class="news-title"><a href="https://www.digitaljournal.com/pr/4861343" target="_blank">Vidafuel Nutrition Closes Oversubscribed $1.075 Million Financing to ...</a></h3>
        <div class="news-source">Digital Journal</div>
        <p>Vidafuel Nutrition Closes Oversubscribed $1.075 Million Financing to Advance its Clinical Nutrition Brand. By. GetNews. Published. October 30, 2020 ...</p>
        <div class="news-date">2020-10-30</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">VidaFuel</span>
        
        <h3 class="news-title"><a href="https://www.bizjournals.com/nashville/news/2018/05/29/jumpstart-foundry-announces-2018-portfolio-brings.html" target="_blank">Jumpstart Foundry invests in Nashville startups VidaFuel and Well ...</a></h3>
        <div class="news-source">The Business Journals</div>
        <p>VidaFuel. Eating healthy can be a challenge for anyone, but it can mean life or death for those with chronic disease. That&#x27;s why Bette Parolini and Dr. Priyank Sharma created VidaFuel â€” a line ...</p>
        <div class="news-date">2018-05-29</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Aloqia</span>
        
        <h3 class="news-title"><a href="https://www.msn.com/en-xl/news/other/shein-increases-use-of-deadstock-fabric-by-40-in-2024/ar-AA1CbCXN" target="_blank">Shein increases use of deadstock fabric by 40% in 2024 - MSN</a></h3>
        <div class="news-source">MSN</div>
        <p>Since 2022, Shein has sourced over 47,900 metres of deadstock fabric through Aloqia, leading to estimated savings of 357,600 cubic metres of water, 7,400 kilograms of chemicals, and 70 metric tons ...</p>
        <div class="news-date">2025-04-03</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Refiberd</span>
        
        <h3 class="news-title"><a href="https://www.msn.com/en-us/money/companies/ebay-invests-300k-in-refiberd-to-boost-circular-fashion-with-ai/ar-AA1CLdiz" target="_blank">eBay invests $300k in Refiberd to boost circular fashion with AI - MSN</a></h3>
        <div class="news-source">MSN</div>
        <p>US company Refiberd has secured a $300,000 investment from online marketplace eBay&#x27;s venture capital arm to strengthen circular fashion efforts using a new AI system.</p>
        <div class="news-date">2025-04-11</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Refiberd</span>
        
        <h3 class="news-title"><a href="https://www.msn.com/en-us/technology/tech-companies/refiberd-wins-trailblazer-2025-with-ai-powered-textile-recycling/ar-AA1GeqUb" target="_blank">Refiberd Wins Trailblazer 2025 With AI-Powered Textile Recycling - MSN</a></h3>
        <div class="news-source">MSN</div>
        <p>Refiberd exemplifies how technological innovation can help bridge longstanding structural gaps in the fashion system,&quot; Federica Marchionni, CEO of the GFA, said.</p>
        <div class="news-date">2025-06-19</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Jiminy&#x27;s</span>
        
        <h3 class="news-title"><a href="https://www.forbes.com/sites/davidriemer/2022/11/07/jiminys-is-fighting-climate-change-one-pet-treat-at-a-time/" target="_blank">Jiminy&#x27;s Is Fighting Climate Change One Pet Treat At A Time - Forbes</a></h3>
        <div class="news-source">Forbes</div>
        <p>Jiminy&#x27;s Chewy Cricket Treat. Jiminy&#x27;s 2022. Carlson tells the story of Lauren, a millennial Jiminy&#x27;s customer who refers to her dog Mordecai as &quot;her son.&quot;</p>
        <div class="news-date">2022-11-07</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Jiminy&#x27;s</span>
        <div class="news-image"><img src="https://static01.nyt.com/images/2025/07/01/multimedia/00SCI-PETTHEORY-FOOD-05-pbkq/00SCI-PETTHEORY-FOOD-05-pbkq-facebookJumbo.jpg" alt="Don&#x27;t Like Eating Insects? Your Pet Might."></div>
        <h3 class="news-title"><a href="https://www.nytimes.com/2025/07/03/science/pets-food-insects-lab-meat.html" target="_blank">Don&#x27;t Like Eating Insects? Your Pet Might.</a></h3>
        <div class="news-source">The New York Times</div>
        <p>Insects and lab-made animal protein have the potential to be far less damaging to the environment. And because pets tend to eat the same thing every day, changing their food &quot;can have real impact,&quot; Ms. Carlson said. &quot;It&#x27;s like flipping a switch. One day it&#x27;s unsustainable, the next, it&#x27;s sustainable.&quot;</p>
        <div class="news-date">2025-07-03</div>
    </div>
    
    <div class="news-card">
        <span class="company-tag">Aeromutable</span>
        
        <h3 class="news-title">No news</h3>
        <div class="news-source"></div>
        <p></p>
        
    </div>
    
    </div>
    <p class="timestamp">Last updated: 2025-07-11<br>Please reload this web page by pressing shortcut keys â€” Command (âŒ˜)-R on Mac or Ctrl+R on Windows â€” if date appears older than a week.</p>
    
    <!-- Chatbot UI - Added title attribute and more visible text -->
    <button class="chat-toggle-button" title="Open Chat Assistant">ðŸ’¬</button>
    <div class="chatbot-container">
        <div class="chatbot-header">
            <span class="chatbot-title">News Assistant</span>
            <span class="close-chat" style="cursor: pointer;">âœ•</span>
        </div>
        <div class="chatbot-messages">
            <div class="message bot-message">
                Hi! I'm your news assistant. Ask me anything about the news articles on this page.
            </div>
        </div>
        <div class="chatbot-input">
            <input type="text" placeholder="Ask a question...">
            <button>Send</button>
        </div>
    </div>
    
    <script>
        const newsData = [{"company": "Unaliwear", "title": "UnaliWear Medical Alert Watch Review (2025) - Forbes Health", "url": "https://www.forbes.com/health/medical-alert-systems/unaliwear-review/", "source": "Forbes", "body": "UnaliWear offers two monitoring subscription options for the Kanega Watch: the annual plan and the monthly plan. For the annual plan, users pay for device setup and 12 months of service upfront.", "date": "2024-02-15", "full_content": "The Forbes Health editorial team is independent and objective. To help support our reporting work, and to continue our ability to provide this content for free to our readers, we receive compensation from the companies that advertise on the Forbes Health site. This compensation comes from two main sources.First, we provide paid placements to advertisers to present their offers. The compensation we receive for those placements affects how and where advertisers\u2019 offers appear on the site. This site does not include all companies or products available within the market.Second, we also include links to advertisers\u2019 offers in some of our articles; these \u201caffiliate links\u201d may generate income for our site when you click on them.\n\nThe compensation we receive from advertisers does not influence the recommendations or advice our editorial team provides in our articles or otherwise impact any of the editorial content on Forbes Health. While we work hard to provide accurate and up-to-date information that we think you will find relevant, Forbes Health does not and cannot guarantee that any information provided is complete and makes no representations or warranties in connection thereto, nor to the accuracy or applicability thereof.\n\nHave a question for Eliene Augenbraun or our other editors?\n\nAsk here for a chance to be featured in a story.\n\nSend a note to\n                                                    Eliene Augenbraun,\n                                                    Carley Prendergast\n                                            and our other editors. We read every email.\n\nKeep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up questions.\n\nThe water-resistant UnaliWear Kanega Watch is a medical alert device that providesautomatic fall detection, 24/7 monitoring and emergency response assistance via voice activation, the press of a button or its easy-to-read screen. It also looks more like a digital watch than a medical alert device.FEATURED PARTNER OFFERWe receive compensation from our partners for Featured Partner Offer placements. While this may influence where their products or services appear on our site, it in no way affects our ratings, which are based on thorough research, solid methodologies and expert advice. Our partners cannot pay us to guarantee favorable review of their products or services.LifeFone At-Home LandlineService starts at $24.95 a monthIn-home range is 1,300 feet and wearable button range is 1,300 feetWith 32-hour backup batteryFree system activationLearn MoreOn LifeFone's Website\n\nUnaliWear, Inc. is the manufacturer of the Kanega Watch, amedical alert watchthat offers 24/7 monitoring via a discreet wearable. \u201cUnalii\u201d is the Cherokee word for \u201cfriend\u201d and \u201cKanega\u201d means \u201cspeak,\u201d so the product\u2019s name translates to \u201cfriend that speaks to you,\u201d according to the company\u2019s website.\n\nThe Texas-based company was founded in April 2013 by CEO Jean Anne Booth, a serial entrepreneur and electrical engineer with 30 years of technology development experience. She retired after selling two other companies she founded, but she was inspired to rejoin the workforce to address problems faced by her mother, who was active but frail and wanted to age in place safely.\n\n\u201c[S]ome of the best stuff I think gets created because of the need, and needs are just not being met in silver tech,\u201d says Booth, noting that none of themedical alert systemsavailable in 2013 would have worked for her mother (theApple Watchdidn\u2019t hit store shelves until April 2015). \u201cThependantis super stigmatizing. And the problem is even with a pendant, you take it off at night because of the threat of choking. Yet the number one cause of injury among older adults is falls\u2014mostly in the bathroom and mostly at night,\u201d explains Booth. \u201cWe realized we could build a watch that you could wear 24/7.\u201d\n\nThe UnaliWear Kanega Watch is disguised discreetly as a digital wristwatch to avoid the potential stigma of wearing a medical alert device. It can interact with the wearer via voice, a push button and large white-on-black text on its screen. The watch is water-resistant, so users can wear it in the shower, although it\u2019s not recommended for swimming. The watch comes with four rechargeable lithium-ion batteries, which can be swapped in and out without taking off the watch.\n\nWhen users first receive the watch, they provide UnaliWear with any relevant medical information.\n\nThe watch connects to the internet and an emergency response operator via Wi-Fi and runs exclusively on the Verizon 4G/5G cellular network nationwide. If an emergency occurs, (the user falls or calls for help), the watch\u2019sGPScan help locate them. It also connects them to an emergency response operator in seconds.\n\nUnaliWear\u2019s emergency response center is a U.S.-based, third-party provider that\u2019s Five Diamond certified by TMA, the monitoring industry\u2019s highest standard. The operators have each customer\u2019s provided medical information on hand to help determine what kind of help should be sent when they receive a call.\n\nTo start talking to the Kanega Watch, say, \u201cFred Astaire,\u201d and give it a command.\n\nSince no two people share identical falling patterns, the watch uses artificial intelligence (AI) to learn about each user\u2019s movements. If the watch detects what might be a fall and the wearer tells the alert center that they didn\u2019t fall, the AI learns to ignore similar movements of that user in the future.\n\nThe watch face includes a black screen with white text and comes in three accent colors: rose gold, champagne gold and black. Each watch strap is black no matter the accent color selected.\n\nUnaliWear offers two monitoring subscription options for the Kanega Watch: the annual plan and the monthly plan.\n\nFor the annual plan, users pay for device setup and 12 months of service upfront. Costs include a $199 one-time setup fee and$59.95 per month for ongoing monitoring and service. The total upfront cost is $918.40.\n\nFor the monthly plan, users pay for device setup and the first month of service upfront. Costs include a $299 one-time setup fee and$69.95 for one month of monitoring service, totaling $368.95 upfront.", "extraction_status": "cached"}, {"company": "Unaliwear", "title": "UnaliWear Kanega Watch Reviews: Written By Customers in 2025", "url": "https://www.consumeraffairs.com/medical-alert-systems/unaliwear-kanega-watch.html", "source": "ConsumerAffairs", "body": "The UnaliWear Kanega Watch is a more discreet alternative to traditional medical alert devices. The watch weighs 49 grams (about 1.7 ounces). It's 1.6 inches in diameter and 0.5 inches thick. It ...", "date": "2025-06-05", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nThe UnaliWear Kanega Watch is a more discreet alternative to traditional medical alert devices. The watch weighs 49 grams (about 1.7 ounces). It's 1.6 inches in diameter and 0.5 inches thick. It ...", "extraction_status": "content_too_short"}, {"company": "BrainCheck", "title": "New and Real-World Research Supports BrainCheck's Cognitive Assessment ...", "url": "https://markets.businessinsider.com/news/stocks/new-and-real-world-research-supports-braincheck-s-cognitive-assessment-and-care-planning-solutions-1032812763", "source": "Business Insider", "body": "Clinicians and patients report high levels of satisfaction with BrainCheck's standard battery, Assess\u2122 and care planning tool, Plan\u2122 Studies confirm Assess can effectively determine severity ...", "date": "2023-11-13", "full_content": "Clinicians and patients report high levels of satisfaction with BrainCheck's standard battery, Assess\u2122 and\u00a0care planning tool, Plan\u2122\n\nStudies confirm Assess can effectively determine severity of cognitive impairment\n\nAUSTIN, Texas,Nov. 13, 2023/PRNewswire/ --BrainCheck, Inc.announced promising new and real-world data supporting BrainCheck's cognitive assessment and care planning solutions was recently presented at The Gerontological Society of America's Annual Scientific Meeting fromNovember 8-12inTampa, FL.Studies confirm clinicians and patients report high levels of satisfaction with BrainCheck's standard battery, Assess\u2122, and care planning tool, Plan\u2122. Research also showed Assess can effectively determine severity of cognitive impairment.\n\n\"More than 7 million Americans are unaware they have mild cognitive impairment (MCI), and 99% of primary care physicians (PCPs) are under-diagnosing the condition,1,2suggesting clinicians and patients are critically in need of a reliable and intuitive solution to help detect MCI earlier,\" saidKim Rodriguez, CEO of BrainCheck. \"BrainCheck's plug-and-play technology is the only solution of its kind that empowers providers with an all-in approach to cognitive care, offering the tools needed to intervene sooner and combat cognitive decline. And now, our latest version offers unparalleled flexibility for use in-clinic or remotely, making this technology even more accessible and easy to implement in the clinical setting.\"\n\nClinicians and Patients Report High-Level of Satisfaction with BrainCheck in Real-World StudyA collaborative quality improvement study with Savannah Neurology Specialists and Dent\u00a0Neurologic Institute evaluated usage, reimbursement and usability of BrainCheck's standard battery, Assess, and care planning tool, Plan and determined patients and clinicians showed a high level of satisfaction with the technology.\n\n\"Our collaboration with BrainCheck has opened a new chapter in our approach to patient care planning and support,\" saidBela Ajtai, MD, Director of the Center for Cognitive Disorders and Brain Health at Dent Neurologic Institute, one of the largest outpatient neurology practices in the U.S. \"Providers appreciate the value of BrainCheck as a promising solution to the increasing demand for cognitive care in an aging population. Patients and care partners value the information and resources presented in care plans. With this leading-edge technology, we are taking a significant step toward improving the quality of care for patients facing cognitive challenges.\"\n\nAccurately Distinguishing Severity of Cognitive ImpairmentResearchers confirmed BrainCheck's standard battery, Assess, effectively distinguished normal cognition (NC) from stages of cognitive decline, which may be associated with mild cognitive impairment (MCI) and dementia (DEM), providing a potentially reliable tool for early detection of cognitive impairment.4\n\n\"With dementia projected to affect 14 million people inthe United Statesand 152 million people globally in the coming decades, early detection of cognitive impairment is paramount but remains a challenge with current clinical protocols,\"\u00a0saidReza Hosseini Ghomi, MD, MSE, neuropsychiatrist and Chief Medical Officer at BrainCheck. \"BrainCheck's platform offers an efficient end-to-end cognitive care solution that can be operationalized in any clinical setting. These research results confirm our standard battery, Assess, is\u00a0a reliable and efficient tool for early detection of impairment, marking a significant advancement in addressing cognitive\u00a0decline.\"\n\nTrusted by hundreds of the country's most prestigious providers and specialists, BrainCheck's clinically-proven platform is the most comprehensive solution commercially available across the cognitive care continuum, streamlining screening, assessment, care planning and monitoring.\n\nAbout BrainCheckTo learn more, please visit braincheck.com.\n\nContact:pr@braincheck.com\n\n1Soeren Mattke et al, Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis, Alzheimer's Research & Therapy (2023). DOI: 10.1186/s13195-023-01272-z2Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population, The Journal of Prevention of Alzheimer's Disease (2023). DOI: 10.14283/jpad.2023.1313Huang B., et al. Implementation of BrainCheck for Cognitive Assessment and Care Planning in the Clinical Setting. Poster presented at The Gerontological Society of America's Annual Scientific Meeting;November 8-12, 2023.Tampa, FL4Huang B., et al. Early Detection of Dementia and Mild Cognitive Impairment With BrainCheck-Assess. Poster presented at The Gerontological Society of America's Annual Scientific Meeting;November 8-12, 2023.Tampa, FL\n\nView original content to download multimedia:https://www.prnewswire.com/news-releases/new-and-real-world-research-supports-brainchecks-cognitive-assessment-and-care-planning-solutions-301985593.html\n\nSOURCE  BrainCheck, Inc.", "extraction_status": "success"}, {"company": "BrainCheck", "title": "BrainCheck Expands First End-to-End Solution for Cognitive Care", "url": "https://finance.yahoo.com/news/braincheck-expands-first-end-end-130000828.html", "source": "Yahoo Finance", "body": "BrainCheck, Inc. launched the next generation of its comprehensive platform and unveiled its latest innovation, BrainCheck\u00ae Screen\u2122, at the Clinical Trials on Alzheimer's Disease (CTAD ...", "date": "2023-10-24", "full_content": "Content extraction failed: 404 Client Error: Not Found for url: https://finance.yahoo.com/news/braincheck-expands-first-end-end-130000828.html", "extraction_status": "success"}, {"company": "Dermala", "title": "DERMALA, A Consumer Dermatology Company, Announces Issuance of the ...", "url": "https://markets.businessinsider.com/news/stocks/dermala-a-consumer-dermatology-company-announces-issuance-of-the-second-u-s-patent-covering-the-use-of-novel-human-microbiome-technology-for-treating-acne-vulgaris-1030899083", "source": "Business Insider", "body": "DERMALA developed a novel technology for enhanced targeted delivery of human microbiome-derived postbiotic metabolites into specific layers of the skin.", "date": "2021-10-26", "full_content": "SAN DIEGO,Oct. 26, 2021/PRNewswire/ --\u00a0DERMALA,\u00a0a consumer dermatology company developing novel, personalized, microbiome-powered solutions for chronic skin conditions, announced today the issuance of the U.S. Patent No. 11,154,522 -COMPOSITIONS AND METHODS FOR TREATING ACNE VULGARIS. This is the second patent in DERMALA's intellectual property portfolio that covers using the human microbiome to treat and prevent acne.\n\nAcneisthe most common skin condition that affectsover\u00a080% of adolescents. It often persists into adulthood with a negative impact on the quality of life. Acne vulgaris is characterized by microbiome dysbiosis associated with an overgrowth ofC. acnesbacteria, followed by inflammation of skin follicles. To date, many strategies have been used to treat acne. However, they often show limited efficacy accompanied by side effects, in part due to suboptimal delivery into the skin and lack of targeting.\n\nDERMALA developed a novel technology for enhanced targeted delivery of human microbiome-derived postbiotic metabolites into specific layers of the skin. This results in higher treatment efficacy due to targeted inhibition ofC. acnesin follicles and reducing inflammation while avoiding side effects.\u00a0The microbiome-derived postbiotics derived from beneficial bacteria help correct the microbiome dysbiosis associated with acne and produce faster and longer-lasting results.\n\n\"Targeted delivery is critical\u00a0for\u00a0overcoming side effects and achieving high treatment efficacy,\" said Dr. Lada Rasochova, founder and CEO of DERMALA. \"Granting of this patent recognizes the uniqueness of our delivery approach and further enhances the value of our microbiome technology as it allows for formulating microbiome-derived ingredients into specific, efficacious, and effective topical products\".\n\nThis patent is an important part of the fast-expanding DERMALA's intellectual property portfolio which focuses on using the human microbiome for improving skin health and treating skin conditions like acne and eczema.\n\nAbout DERMALADERMALA, Inc. is aSan Diego-based consumer dermatology company leveraging a scientific understanding of the human microbiome and data analytics to develop novel treatments for chronic skin conditions. The company's #FOBO\u00ae(Fear of Breaking Out) Kit, a personalized, microbiome-powered solution for acne, combines patented topical treatments and oral supplements with the DERMALA Acne Tracker app that customers use to track their skin health and get their product formulations optimized. For more information, visitwww.dermala.com.\n\nPress Contact:Erica@LazarusPR.com\n\nView original content to download multimedia:https://www.prnewswire.com/news-releases/dermala-a-consumer-dermatology-company-announces-issuance-of-the-second-us-patent-covering-the-use-of-novel-human-microbiome-technology-for-treating-acne-vulgaris-301408177.html\n\nSOURCE  DERMALA", "extraction_status": "success"}, {"company": "Dermala", "title": "DERMALA CEO AND FOUNDER INVITED AS SPEAKER AND ... - Markets Insider", "url": "https://markets.businessinsider.com/news/stocks/dermala-ceo-and-founder-invited-as-speaker-and-panelist-to-two-upcoming-industry-conferences-1031304308", "source": "Business Insider", "body": "DERMALA, Inc. is a San Diego -based company leveraging a scientific understanding of the human microbiome and data analytics to develop novel personalized treatments for chronic skin conditions.", "date": "2022-03-24", "full_content": "SAN DIEGO,March 24, 2022/PRNewswire/ -- DERMALA, a consumer dermatology company developing novel, personalized, microbiome-powered solutions for chronic skin conditions such as acne and eczema, announces its involvement in two prominent industry meetings. Dr.Lada Rasochova, the founder and CEO ofDERMALA, will participate as a speaker and panelist at the Personalized BeautyUSAandMicrobiome&ProbioticsR&D & Business Collaboration ForumUSAconferences.\n\nPersonalized BeautyUSA, a Personalized Beauty Summit, is taking place inSan Francisco, CAonMarch 30tand 31. Dr Rasochova will be a panelist on two topics - 'The Role of the Microbiome in Personalized Skincare' and 'Creating an End-to-End Customer Experience.' DERMALA will share insights on providing successful product personalization and continuous treatment optimization and building customer relationships by utilizing treatment progress tracking via selfies and various skin tests, understanding the microbiome changes, and deploying data analytics to present the best product options to customers.\n\n\"Personalization is becoming fundamental to the customer journey,\" said Dr. Lada Rasochova. \"Our priority is to build relationships with our customers, and it\u00a0is only by understanding large amount of data that you can fully realize personalized skincare and develop that relationship.\"\n\nDERMALA will also attend the Microbiome & Probiotics R&D & Business Collaboration ForumUSAmeeting that is held onMarch 29and 30\u00a0inSan Diego, CA.DERMALA will participate in discussions of the most cutting-edge microbiome and probiotics research, challenges, and opportunities at this world-renowned event. Dr. Rasochova will review microbiome research and clinical data during her talk 'Acne and the Human Microbiome' in the Skin and Cosmeceuticals session. During the 'Dosing in the Microbiome \u2013 Dealing with The Great Unknown'\u00a0panel discussion, Dr. Rasochova will provide insights into the research, product development, and manufacturing of microbiome-based products.\n\n\"We look forward to sharing our research, customer experience, and results of personalizing microbiome-based skincare products,\"\u00a0said Rasochova. \"It is a tremendous opportunity to share our insights as both speaker and panelist at these two upcoming meetings.\"\n\nAll DERMALA products are based on cutting-edge human microbiome science. They are formulated with patented microbiome-derived prebiotics, probiotics, and postbiotics that improve skin and gut health naturally.\n\nAbout DERMALADERMALA, Inc. is aSan Diego-based company leveraging a scientific understanding of the human microbiome and data analytics to develop novel personalized treatments for chronic skin conditions. For more information, visitwww.dermala.com.\n\nMedia Contact:Erica Lazaruserica@lazaruspr.com\n\nView original content to download multimedia:https://www.prnewswire.com/news-releases/dermala-ceo-and-founder-invited-as-speaker-and-panelist-to-two-upcoming-industry-conferences-301509331.html\n\nSOURCE  DERMALA", "extraction_status": "cached"}, {"company": "Oralucent", "title": "No news", "url": "", "source": "", "body": "", "date": "2025-07-11", "full_content": "", "extraction_status": "not_attempted"}, {"company": "Flowly", "title": "Relaxation app startup Flowly rolls out program for providers", "url": "https://www.fiercehealthcare.com/digital-health/relaxation-app-vr-startup-flowly-rolls-out-program-providers", "source": "Fierce Healthcare", "body": "Flowly, an app for autonomic nervous system regulation, has launched a program for providers, the company has shared exclusively with Fierce Healthcare. | Through the program, ...", "date": "2023-03-13", "full_content": "Flowly, an app for autonomic nervous system regulation, has launched a program for providers, the company has shared exclusively with Fierce Healthcare.\n\nThrough the program, providers will receive a virtual reality headset, a heart rate sensor, an onboarding session and access to a portal tracking patient progress.\n\nFounded in 2020, Flowly relies on the stimulating and immersive nature of VR to draw a user\u2019s attention away from pain. By being able to visualize one\u2019s heart rate and breathing, users can learn to regulate their nervous system. The company has gone through several clinical trials, received a grant from the National Institutes of Health and also participated in Y Combinator.\n\nDuring COVID-19, Flowly saw an influx in providers interested in its product\u2014for use on themselves, co-founder and CEO Celine Tien told Fierce Healthcare. They were also eager to receive information about innovative ways to use pain management and anxiety therapies. \u201cThe problem with our healthcare model today is that so many providers live in their own silos,\u201d Tien said.\n\nTo help bridge gaps in knowledge, Flowly created a founding board of physicians, with 15 active members, where they share creative ways of using Flowly in practice. Members of the board also get access to the latest research, data and features from Flowly and can offer feedback to improve the product. Some members also work with Flowly to design lectures on their domain expertise. Nearly all members of the board have used Flowly themselves, Tien said.\n\nJaimee Arnoff, Ph.D., a licensed clinical psychologist specializing in young adults, initially heard about Flowly on a podcast. As someone with chronic pain, Arnoff reached out to try the product. \u201cAs a provider, I always love to try any app,\u201d Arnoff told Fierce Healthcare, especially one she might suggest to her clients.\n\nAfter using Flowly for a few months, she was convinced it was worth recommending to her patients as an option. \u201cIt was great to kind of focus on something so all-consuming,\u201d Arnoff said. \u201cIt\u2019s beautiful; it\u2019s relaxing.\u201d\n\nPatients can use Flowly before, during or after a treatment session to help calm their nervous system. \u201cThere are many days with clients where we are asking them to lean into this very uncomfortable place,\u201d Arnoff said. \u201cFlowly is a great way to kind of debrief and kind of come down from a heightened state of emotional or physical state that we might find ourselves in together.\u201d\n\nSome of Arnoff\u2019s patients buy Flowly for their personal use outside of treatment sessions.\n\nFlowly currently has more than 10,000 users and is so far used by more than 100 providers.", "extraction_status": "cached"}, {"company": "Flowly", "title": "Sponsored App Review: Flowly - Android Headlines", "url": "https://www.androidheadlines.com/2014/02/sponsored-app-review-flowly.html", "source": "Android", "body": "Description: Flowly (which some of you might have known as Android Hub) is an Android app that's quite literally, all about Android. It's essentially a self-contained RSS reader that's full ...", "date": "2014-02-19", "full_content": "Description:Flowly (which some of you might have known as Android Hub) is an Android app that\u2019s quite literally, all about Android. It\u2019s essentially a self-contained RSS reader that\u2019s full of the best Android news sites, enabling you to keep up to date about all things Android. We\u2019re included in the list of news sources, as are Android Central, Android Police and the XDA Portal. It\u2019s a tablet-optimized app as well, making it perfect for those times when all you want to do is read about Android in leisure on that nice big Galaxy Note 12.2 you\u2019re waiting custom ROMs to appear on. With a night theme, and more available in the Pro version, Flowly is an essential app to keep on top of news if you\u2019re an Android enthusiast. The question is of course, how good an app is Flowly?\n\nHow it Works:After a quick download fromthe Play Store\u2013 of which there\u2019s also aPro versionwith added features \u2013\u00a0you\u2019re able to start using Flowly as you would any other app.\n\nAfter taking a look at what\u2019s new with the app, you\u2019re sent straight to the list of Android news on tap. With sites on the left and all the newest news on the right-hand side of the display.\n\nThe app can be used in portrait as well, and looks particularly nice on KitKat devices in its dark night theme.\n\nThere\u2019s a YouTube portal as well, which easily gets you to the channels of all the included Android sites. Which is great for when new devices comes out and you want to drool over some unboxings.\n\nOpinion:Flowly, is a great app for those that are looking to get hold of Android news and content. After all, that is the app\u2019s sole purpose and it fulfills that brilliantly. It looks great on tablets and the whole app is nice and smooth. The Pro version is well worth looking into as well, as it has a number of added features and isn\u2019t all that expensive. Where or not Flowly is an app for you depends on how interested in Android you are, if you\u2019re a die-hard fan then you need to install this app. For keeping abreast of all the most important Android news out there, Flowly is the app to go with. Sure, you could create a an RSS feed with all of your favorite Android sites, but that takes time and not everyone has the patience for that. Apps like Appy Geek are good alternatives, but again they\u2019re not as focused and can feel cluttered.\n\nRatings\n\nPros\n\nCons\n\nConclusion:Flowly is one of those apps that any Android enthusiast really ought to have installed. It\u2019s certainly not perfect, but it fulfills what it sets out to do very well and there are no glaring issues with the app. Sure, on the surface it\u2019s just an RSS app full of Android feeds. What if that\u2019s all you really need though? It\u2019s a very efficient way of grouping all of this news together and the developer also manages to avoid bias, too. While it would be nice to be able to add custom feeds in the app, I can understand why it\u2019s not included right now and someone like myself can certainly see the appeal of some quality curation such as this. Flowly is a good app for those that are heavily involved in Android.", "extraction_status": "cached"}, {"company": "Rosy Wellness", "title": "Dar\u00e9 Bioscience and Rosy Wellness Announce Strategic Collaboration to ...", "url": "https://finance.yahoo.com/news/dar-bioscience-rosy-wellness-announce-120000637.html", "source": "Yahoo Finance", "body": "Collaboration will leverage Rosy Wellness' extensive reach and community of over 250,000 women Rosy Wellness is a multi-award winning app recommended by 8,000+ healthcare professionals Dar\u00e9 ...", "date": "2025-06-04", "full_content": "Collaboration will leverage Rosy Wellness\u2019 extensive reach and community of over 250,000 women\n\nRosy Wellness is a multi-award winning app recommended by 8,000+ healthcare professionals\n\nDar\u00e9 expects to start recording revenue in the 4th quarter this year\n\nSAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- Dar\u00e9\u00a0Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, and Rosy Wellness, a pioneering digital platform focused on providing lifespan support for women, today announced a strategic collaboration to support the upcoming marketing and consumer and healthcare provider awareness campaign for Dar\u00e9\u2019s DARE to PLAY Sildenafil Cream.\n\nDar\u00e9\u2019s DARE to PLAY Sildenafil Cream is a proprietary topical formulation of sildenafil citrate, the same active ingredient in Viagra\u00ae, developed specifically to increase blood flow locally to genital tissues, which is part of the sexual arousal response in women. The company is targeting availability by prescription in the United States in the 4thquarter 2025 as a compounded drug under Section 503B of the FDCA.\n\nThis partnership brings together Dar\u00e9\u2019s clinical expertise and innovation in women's health with Rosy\u2019s digital reach and content-driven community engagement model, which includes a community of 250K+ women. Concerns with arousal were reported by 65% of those women who completed the Female Sexual Function Index screener questionnaire. The collaboration will center on educational outreach, consumer and healthcare provider engagement, and companion digital support to destigmatize conversations around female sexual health and promote awareness of DARE to PLAY Sildenafil Cream, helping women regain intimacy and satisfaction in their lives.\n\n\u201cFemale sexual health remains significantly underserved, and we believe our DARE to PLAY Sildenafil Cream represents a meaningful advancement,\u201d said Sabrina Martucci Johnson, President and CEO of Dar\u00e9 Bioscience. \u201cPartnering with Rosy allows us to connect with women in a trusted, authentic space that encourages open discussion and education about sexual wellness.\u201d\n\nRosy, known for its innovative and evidence-based approach to women\u2019s sexual health through education, CBT-based (Cognitive Behavioral Therapy) exercises, expert-led health coaching, and community support, will support the launch with a comprehensive digital strategy including educational campaigns, and a companion care platform aimed at increasing understanding of female sexual health and supporting DARE to PLAY Sildenafil Cream\u2019s users throughout their journey.\n\n\u201cAt Rosy, we\u2019re committed to closing gaps in women\u2019s healthcare with evidence-based, accessible solutions,\u201d said Lyndsey Harper, MD, Founder and CEO of Rosy. \u201cThis partnership with Dar\u00e9 accelerates our efforts to bring much needed attention and resources to sexual wellness, a historically stigmatized area. Together, we can expand sexual wellness education, access, and support for women.\"\n\nThe partnership underscores a shared commitment to advancing sexual health equity and ensuring women have access to both the information and solutions they need.\n\nFor more information, please visitwww.darebioscience.comandwww.meetrosy.com.\n\nAbout Rosy Wellness\n\nRosy is a leading women's health platform dedicated to empowering women with evidence-based resources, expert support, and community connection, starting with sexual health and expanding across the full spectrum of the health of women. Founded by Lyndsey Harper, a board-certified OB-GYN, Rosy addresses long-overlooked aspects of women's care through an accessible digital platform that combines personalized education, self-guided tools, community, and health coaching.\n\nWhether tackling issues like sexual dysfunction, menopause, migraine, or emotional well-being, Rosy provides judgment-free, medically backed support designed for real life. By combining evidence-based support with user-friendly technology, Rosy is redefining how women take charge of their health and experience more fulfilling lives.\n\nAbout Dar\u00e9 Bioscience\n\nDar\u00e9 Bioscience is a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority. Dar\u00e9 believes that innovation does not have to start from scratch. The company\u2019s goal is to bring to market as soon as practicable innovative evidence-based solutions that address decades of unmet needs in women\u2019s health and enhance outcomes and convenience, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. The potential products Dar\u00e9 identifies, in many cases, already have clinical proof of concept or existing safety data for the active ingredient that the company leverages. This provides optionality and flexibility, in many cases, in how Dar\u00e9 seeks to bring solutions to market in ways designed to optimize access for women in a fiscally responsible manner.\n\nThe first FDA-approved product to emerge from Dar\u00e9\u2019s portfolio of women\u2019s health product candidates is XACIATO\u2122 (clindamycin phosphate) vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Visit www.xaciato.com for information about XACIATO. Dar\u00e9\u2019s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene\u00ae, a novel, hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil citrate, the active ingredient in an oral erectile dysfunction drug for men, to treat female sexual arousal disorder (FSAD); and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. To learn more about Dar\u00e9\u2019s full portfolio of women\u2019s health product candidates and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.\n\nDar\u00e9 Bioscience leadership has been named on the Medicine Maker\u2019s Power List and Endpoints News\u2019 Women in Biopharma and Dar\u00e9's CEO has been honored as one of Fierce Pharma\u2019s Most Influential People in Biopharma for Dar\u00e9\u2019s contributions to innovation and advocacy in the women\u2019s health space.\n\nDar\u00e9 may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Dar\u00e9 will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Dar\u00e9 posts on its investor relations website or through social media channels may be deemed to be material information. Dar\u00e9 encourages investors, the media, and others interested in the company to review the information Dar\u00e9 posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Dar\u00e9\u2019s website.\n\nForward-Looking Statements\n\nDar\u00e9 cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cdesign,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201ccould,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccontemplate,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cobjective,\u201d \u201con track,\u201d or the negative version of these words and similar expressions. In this press release, forward-looking statements include, but are not limited to, statements relating to Dar\u00e9\u2019s go-to-market strategies; Dar\u00e9\u2019s plans and timing for making its proprietary formulation of sildenafil citrate available by prescription in the U.S. as a compounded drug via Section 503B of Federal Food, Drug, and Cosmetic Act (FDCA); the market opportunity for the product and its ability to gain market acceptance; expected timing of revenue from sales; the potential benefits of Dar\u00e9\u2019s collaboration with Rosy Wellness; and Dar\u00e9\u2019s development plans for the investigational products in its portfolio and their respective potential to complete clinical development and obtain regulatory approval. As used in this press release, \u201cfirst-in-category\u201d is a forward-looking statement relating to the potential of a product candidate to represent a new category of product if it were to receive marketing approval for the indication for which it is being developed because Dar\u00e9 believes it would address a need in women\u2019s health that is not being met by existing U.S. Food and Drug Administration (FDA)-approved products. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Dar\u00e9\u2019s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: Dar\u00e9\u2019s ability to raise additional capital when and as needed to execute its business strategy and continue as a going concern; the risk of delisting of Dar\u00e9\u2019s common stock from Nasdaq; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Dar\u00e9\u2019s ability to raise additional capital or on Dar\u00e9\u2019s operations, financial results and condition, and ability to achieve current plans and objectives; Dar\u00e9\u2019s ability to enter into and maintain third-party collaborations to facilitate access to the solutions Dar\u00e9 intends to bring to market as compounded drugs or consumer health products and Dar\u00e9\u2019s reliance on those third parties; the performance of Section 503B-registered outsourcing facilities and other third parties on which Dar\u00e9 will rely to execute its expanded business strategy; the risk that the FDA could stop permitting Section 503B-registered outsourcing facilities to compound the drug substances in the proprietary formulations Dar\u00e9 intends to bring or brings to market; the degree of market demand and acceptance for the products Dar\u00e9 brings to market; Dar\u00e9\u2019s reliance on third parties to manufacture and conduct clinical trials and preclinical studies of its product candidates and commercialize XACIATO\u2122 (clindamycin phosphate) vaginal gel 2% and future products, if any; the risk that the current regulatory pathway known as the FDA\u2019s 505(b)(2) pathway for drug product approval in the U.S. is not available for a product candidate as Dar\u00e9 anticipates; Dar\u00e9\u2019s ability to achieve the product development and other milestones required for it to receive payments under its subaward and grant agreements; the potential for termination of the subaward and grant agreements before Dar\u00e9 receives additional payments; the limits on Dar\u00e9\u2019s ability to sell stock under its equity line arrangement at times it may desire to raise additional capital; Dar\u00e9\u2019s ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; failure or delay in starting, conducting and completing clinical trials of a product candidate and the inherent uncertainty of outcomes of clinical trials; Dar\u00e9\u2019s ability to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates; Dar\u00e9\u2019s dependence on third parties to conduct clinical trials and manufacture and supply clinical trial material and commercial product; the risks that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate and that interim data or results from a particular clinical study do not necessarily predict the final results for that study; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Dar\u00e9\u2019s interpretation of or conclusions regarding data from clinical studies of its product candidates; the risk that development of a product candidate requires more clinical or nonclinical studies than Dar\u00e9 anticipates; the loss of, or inability to attract, key personnel; the risk that developments by competitors make Dar\u00e9\u2019s product or product candidates less competitive or obsolete; difficulties establishing and sustaining relationships with development and/or commercial collaborators; failure of Dar\u00e9\u2019s product or product candidates, if approved, to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors; Dar\u00e9\u2019s ability to retain its licensed rights to develop and commercialize a product or product candidate; Dar\u00e9\u2019s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its product and product candidates; Dar\u00e9\u2019s ability to adequately protect or enforce its, or its licensor\u2019s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Dar\u00e9\u2019s product candidates which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Dar\u00e9\u2019s products or product candidates or the business activities of Dar\u00e9, its commercial collaborators or other third parties on which Dar\u00e9 relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; cybersecurity incidents or similar events that compromise Dar\u00e9\u2019s technology systems or those of third parties on which it relies and/or significantly disrupt Dar\u00e9\u2019s business; and disputes or other developments concerning Dar\u00e9\u2019s intellectual property rights. Dar\u00e9\u2019s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Dar\u00e9\u2019s risks and uncertainties, you are encouraged to review its documents filed with the SEC including Dar\u00e9\u2019s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Dar\u00e9 undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.\n\nContacts:\n\nDar\u00e9 Bioscience Investor Relationsinnovations@darebioscience.com\n\nSource: Dar\u00e9 Bioscience, Inc.", "extraction_status": "success"}, {"company": "Rosy Wellness", "title": "rosy wellness Coverage - MedCity News", "url": "https://medcitynews.com/tag/rosy-wellness/", "source": "MedCity News", "body": "In recent years, providers have been increasingly conducting tech pilots to see which solutions can best improve their clinical and operation success. During a panel at MedCity News' INVEST ...", "date": "2024-09-19", "full_content": "In recent years, providers have been increasingly conducting tech pilots to see which solutions can best improve their clinical and operation success. During a panel at MedCity News\u2019 INVEST Digital Health conference in Dallas, healthcare leaders shared their insight on how startups can best serve their provider partners during these pilots.", "extraction_status": "success"}, {"company": "De Oro Devices", "title": "De Oro Devices Names Cori Lathan, PhD, as New CEO - Yahoo Finance", "url": "https://finance.yahoo.com/news/oro-devices-names-cori-lathan-220500791.html", "source": "Yahoo Finance", "body": "Dr. Lathan joins De Oro Devices from her previous role as CEO at AnthroTronix, where she successfully invented, developed, and commercialized medical technology for over 20 years before leading ...", "date": "2024-01-18", "full_content": "Dr. Lathan brings two decades of medical technology with her to drive the health tech startup forward\n\nSAN LUIS OBISPO, CA / ACCESSWIRE / January 18, 2024 /De Oro Devices, a leading innovator in medical technology for the aging and mobility-impaired population, is pleased to announce the appointment of Dr. Cori Lathan as its new Chief Executive Officer (CEO). In her new role, Lathan will focus on continuing the rapid growth De Oro Devices has seen by exploring new partnerships across the healthcare industry and working to advance its innovative technology.\n\nDr. Lathan joins De Oro Devices from her previous role as CEO at AnthroTronix, where she successfully invented, developed, and commercialized medical technology for over 20 years before leading the company through a successful exit. She has been recognized by the World Economic Forum as a Technology Pioneer and Young Global Leader and is the founding co-chair of their Global Futures Council on Human Augmentation and Longevity. Her expertise in brain health and age tech as well as mobility products positions her as a visionary leader capable of driving De Oro Devices to new heights.\n\n\"We are thrilled to welcome Dr. Cori Lathan as our new CEO,\" said Sidney Collin, Board Member, Co-founder, President and CTO at De Oro Devices. \"Her exceptional leadership, deep industry knowledge, and commitment to innovation align perfectly with our mission. As we continue to improve the lives of the mobility-impaired, I know Dr. Lathan is the right leader to take De Oro Devices forward.\"\n\n\"I am honored and excited to lead De Oro Devices into its next chapter of growth and innovation,\" said Dr. Cori Lathan. \"The team's dedication to changing lives through developing transformational medical technologies is inspiring, and I look forward to building on the company's successes to make a meaningful impact on technology for the aging population globally.\"\n\nDe Oro Devices is at the forefront of medical technology, known for creating the first non-invasive cueing technology that can be used with any mobility aid to improve mobility and decrease falls for people with mobility impairments. Learn more at www.getnexstride.com.\n\nAbout De Oro Devices\n\nDe Oro Devices is an award-winning tech startup that's restoring mobility, independence, and a higher quality of life to individuals with mobility challenges and/or heightened fall risk. De Oro's flagship product, NexStride, is a small, unobtrusive device that can attach to any assisted walking tool (i.e., cane, walker, or rollator), which leverages visual and auditory cueing technology to reduce fall risk and improve mobility. Learn more atwww.getnexstride.com.\n\nContact Information\n\nWilliam Thompsonpr@deorodevices.com\n\nSOURCE:De Oro Devices\n\nView the originalpress releaseon newswire.com.", "extraction_status": "cached"}, {"company": "De Oro Devices", "title": "New device helps Clovis veteran with Parkinson's walk again", "url": "https://abc30.com/parkinsons-disease-nexstride-device-de-oro-devices-clovis-veteran-able-to-walk/12728394/", "source": "ABC30 Action News", "body": "The simple act of walking can be challenging for those living with Parkinson's disease, which affects movement. However, a Clovis veteran is now on the move with the help of a newly-invented device.", "date": "2023-01-25", "full_content": "The device essentially uses the same visual and auditory signals or cues used in physical therapy.\n\nCLOVIS, Calif. (KFSN) --The simple act of walking can be challenging for those living with Parkinson's disease, which affects movement.\n\nHowever, a Clovis veteran is now on the move with the help of a newly-invented device.\n\n\"It feels like your feet are stuck in cement,\" explained Patrick Hallmark. \"A lot of people who have Parkinson's, you'd be going through a doorway or whatever, and your feet -- you just cannot move your feet.\"\n\nThe 63-year-old has a condition called \"Freezing of Gait,\" which can come with Parkinson's.\n\nIt can lead to falls and hospitalizations.\n\nFor Hallmark, it also came with a loss of independence.\n\n\"If I didn't have my wife or daughter with me, I would really have a hard time out going to stores and everything,\" he said.\n\nThat's all changed with a device as small as his palm.\n\n\"This has done wonders,\" Hallmark said, as he shows his NexStride device.\n\nThrough a Parkinson's support group, Hallmark learned about NexStride and immediately bought the device.\n\nNow he's walking, despite his condition.\n\nSidney Collin, CEO of De Oro Devices, explained why walking can be hard for people with Freezing of Gait.\n\n\"There's a disconnect between the brain and the body, and it makes it so that when the brain is sending that signal to initiate movement, it doesn't get to the motor neurons that are activating the muscles,\" she said.\n\nCollin, a biomedical engineer, created NexStride for a veteran while she was in college.\n\nThe device essentially uses the same visual and auditory signals or cues used in physical therapy.\n\n\"The visual cue that we use is a green laser line projected onto the floor in front of you. The auditory cue is a metronome,\" she explained. \"So you visualize yourself stepping over that green laser line, stepping to the beat of the metronome. Just by changing the intention behind the movement, by setting that goal, we're changing the part of the brain that's been activated, that allows someone to be able to restore mobility.\"\n\nCollin is happy to see NexStride restoring mobility for people like Hallmark.\n\n\"I am able to walk or take my dog for walks,\" Hallmark said. \"I'm able to get out and go shopping, grocery shopping for my wife -- just do different things like that.\"\n\nThe device is $499 and it's 100% covered for veterans through Veterans Affairs, as well as the Parkinson's Wellness Fund organization.", "extraction_status": "cached"}, {"company": "Partum Health", "title": "INVEST Pitch Perfect Spotlight: How Partum Health Is Working To ...", "url": "https://medcitynews.com/2023/06/maternal-healthcare-postpartum-birth-fertility/", "source": "MedCity News", "body": "Partum Health, a maternal health startup, recently won the consumer/employer track of the MedCity News INVEST Pitch Perfect contest. The direct-to-consumer company supports families during ...", "date": "2023-06-03", "full_content": "Meghan Doyle (left), CEO of Partum Health, accepts the MedCity INVEST Pitch Perfect award from Arundhati Parmar (right), editor-in-chief of MedCity News, May 24.\n\nMeghan Doyle, co-founder and CEO of Partum Health, was working at a consulting firm in the healthcare sector when she first became a mom. It was during this time that she realized how confusing maternal healthcare really is.\n\n\u201cI think a lot of the things I was talking to my clients about \u2014 like the digital front door and how we build around patient-centered outcomes and multidisciplinary care models \u2014 were really absent when it came to my maternal care journey,\u201d Doyle said in an interview. \u201cThat made a big impression on me.\u201d\n\nBreak down the silos. Take control of your provider data.\n\nWhat was absent was care for needs other than actual pregnancy care, like mental health and physical therapy. Postpartum care was also seriously lacking. Drawing from her experience, Doyle went on to create Chicago-basedPartum Healthin 2020.Judges crowned Partum Health the winner of the consumer/employer track of theMedCity News INVEST Pitch Perfect conteston May 24, preferring it over four other companies.\n\nPartum Health, a direct-to-consumer company, supports families during fertility, pregnancy and postpartum. It currently only serves patients in Illinois, but is looking to expand nationally. It offers doula care (during birth and postpartum), lactation consultants, physical therapy, nutrition support, mental health services and acupuncture. Patients can meet with the care team in the provider\u2019s office, the patient\u2019s home or via telehealth. They can also chat with the care team through Partum\u2019s app.\n\n\u201cI think the reality is, if you want to have a great postpartum experience, you actually have to start planning and doing preventative care during your pregnancy,\u201d Doyle said. \u201cThen we also know that, for example, when people are in the midst of fertility treatments, there\u2019s a really high incidence of mental health challenges, and also nothing really built into that care delivery to bring mental health side-by-side with your fertility journey. There may also be instances where people need support with the physical side from [physical therapy], things like nutrition, that can really aid in supporting optimal fertility, pregnancy and postpartum.\u201d\n\nPartum Health was chosen as the winner of the Pitch Perfect contest because it is filling an \u201cunmet market need,\u201d said Shawn Ellis, managing partner ofDistributed Venturesand a judge for the contest.\n\nHealthcare is drowning in chaos\u2014from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.\n\n\u201cThere was a consensus that Partum is coordination of different specialist care that\u2019s really, really needed during pregnancy and post pregnancy,\u201d Ellis said. \u201c[I] loved the coordination of care, loved the very consumer-centric approach, patient-centric approach.\u201d\n\nWhile Partum is a direct-to-consumer company, it is in-network with Blue Cross Blue Shield, Aetna, UnitedHealthcare and Cigna for its clinical services. It functions in a fee-for-service model, in which clinical care is usually reimbursed through insurance and non-clinical services like doula care is paid out of pocket or through a health savings account or flexible spending account.Down the line, the company aims to engage in more payer relationships (including Medicaid), as well as work with employers.\n\nPartum has received interest from investors as well, raising a little over $1 million in a pre-seed round from angel investors. The startup is currently raising\u00a0its seed round.\n\nOther maternal health companies are gaining funding as well. Maven Clinic raised$90 millionin Series E funding in November. The company offers care including fertility, maternity and pediatric support. Oula \u2014 which provides midwifery, obstetrics and pregnancy education \u2014 raised more than$19 millionin January.\n\nPartum Health\u2019s ultimate goal is to expand the scope of what\u2019s considered needed in pregnancy care, Doyle said.\n\n\u201cOur aim is that every family \u2014 just like you see an obstetrician or you see a reproductive endocrinologist if you\u2019re going through fertility \u2014 they also have access to mental health and physical therapy and doula care,\u201d Doyle said. \u201cThat\u2019s really the shift that we\u2019re trying to create. The default model really needs to be expanded to include these specialists because that\u2019s what the families are looking for. And that\u2019s what\u2019s going to move the needle on the health complications and issues that people are experiencing today.\u201d\n\nPhoto: MedCity News", "extraction_status": "cached"}, {"company": "Partum Health", "title": "Partum Health Expands to Dallas, On A Mission to Elevate Maternal Care ...", "url": "https://finance.yahoo.com/news/partum-health-expands-dallas-mission-124100615.html", "source": "Yahoo Finance", "body": "Partum Health, the Chicago-based maternal health startup that offers direct-to-consumer interdisciplinary pregnancy and postpartum care, is expanding to Dallas, the brand's third market.", "date": "2024-08-21", "full_content": "The maternal health start-up provides expert support for growing families through proactive care from pre-conception through early parenthood.\n\nCHICAGO,Aug. 21, 2024/PRNewswire/ --Partum Health, theChicago-based maternal health startup that offers direct-to-consumer interdisciplinary pregnancy and postpartum care, is expanding toDallas, the brand's third market. Partum was founded inChicagoin 2021 and expanded toHoustoninNovember 2023afterraising$3.1 millionin seed funding.\n\nInthe United States, more women die each year of pregnancy-related complications than in any other developed country, with the majority of those deaths happening between one week and one year of giving birth. And inTexas, the need is especially acute. A2022 studypublished by the Texas Medical Association ranked the state 50th among all states in access to high-quality prenatal and maternal care, citing barriers to health care before and after their hospital stay as a key factor. Moreover, areportlast year by the Texas Health and Human Services Commission found that 90% of the state's pregnancy-related deaths are preventable, recommending an improvement in care coordination and access to comprehensive health services to achieve better outcomes.\n\nPartum Health was founded with a mission to change the standard of maternal care after its founders witnessed the huge gap between the care they needed and what they actually received during their own families' perinatal experiences.\n\nIn addition to a comprehensive network of postpartum specialty providers across lactation, mental health, physical therapy and more, Partum families also have a dedicated care coordinator. This go-to contact helps parents make informed decisions, schedule appointments, navigate insurance and is available 24/7 via text. To help remove barriers to access, Partum's services are available virtually and in-home to meet the dynamic needs of modern families.\n\n\"We built Partum to help bridge the gap in comprehensive maternal health and improve outcomes during the critical postpartum period. Our offerings are focused on preventing the most common complications of pregnancy, including perinatal mood and anxiety disorders and avoidable C-sections, among others. We look forward to partnering with OBs and Midwives acrossDallas/Fort Worthto provide wraparound, interdisciplinary care to their patients,\" saidMeghan Doyle, co-founder and CEO of Partum Health.\n\nTo support its launch inDallas, Partum is hosting gatherings to engage local communities around women's health.Collaborative Care in Women's Healthwill bring together women's health providers across the spectrum of care to discuss how to better integrate in service of improved patient outcomes.Reconnecting and Finding Intimacywill convene experts for an honest discussion on social and emotional wellbeing postpartum. Partum will also be meeting with local expectant families at the Prego Expo Convention.\n\nAbout Partum Health\n\nPartum Health believes all families deserve comprehensive, whole-person care that supports their mental, physical and emotional health needs throughout the pregnancy and postpartum experience. Through digital care coordination and patient education as well as interdisciplinary services offered virtually and in person by expert care providers, Partum Health makes this a reality for families. For more information, please visitwww.partumhealth.comor follow Partum Health onInstagram,Facebook,XandLinkedIn.\n\nMedia Contact:Sona Jones877-381-5221382123@email4pr.com\n\nView original content to download multimedia:https://www.prnewswire.com/news-releases/partum-health-expands-to-dallas-on-a-mission-to-elevate-maternal-care-throughout-texas-302226913.html\n\nSOURCE Partum Health", "extraction_status": "success"}, {"company": "Fort Health", "title": "Fort Health Partners with Colleva to Train its Therapists with AI ...", "url": "https://www.victoriaadvocate.com/fort-health-partners-with-colleva-to-train-its-therapists-with-ai-patient-avatars-for-role/article_1aabcc2c-daf6-58b1-a558-b960053187f5.html", "source": "The Victoria Advocate", "body": "Agentic AI Custom Training Scenarios Result in 83% of Clinicians Feeling More Prepared and 95% Able to Apply What They Have Learned \"AI-powered avatar simulations are revolutionizing therapist ...", "date": "2025-03-18", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nAgentic AI Custom Training Scenarios Result in 83% of Clinicians Feeling More Prepared and 95% Able to Apply What They Have Learned \"AI-powered avatar simulations are revolutionizing therapist ...", "extraction_status": "content_too_short"}, {"company": "Fort Health", "title": "At Fort Health, My Teen Finally Found a Therapist He Doesn't Hate", "url": "https://www.msn.com/en-us/health/other/at-fort-health-my-teen-finally-found-a-therapist-he-doesn-t-hate/ar-AA1uiCeX", "source": "MSN", "body": "My teen has tried three different online therapy services, but Fort Health was the best experience by far. Read my full review to find out why its personalized experience, user-friendly sign-up ...", "date": "2024-11-18", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nMy teen has tried three different online therapy services, but Fort Health was the best experience by far. Read my full review to find out why its personalized experience, user-friendly sign-up ...", "extraction_status": "content_too_short"}, {"company": "RubyWell", "title": "No news", "url": "", "source": "", "body": "", "date": "2025-07-11", "full_content": "", "extraction_status": "not_attempted"}, {"company": "Atlantic Sea Farms", "title": "tasteMAKERS | Atlantic Sea Farms | Season 2 | Episode 201 - PBS", "url": "https://www.pbs.org/video/atlantic-sea-farms-b1pe1x/", "source": "PBS", "body": "Atlantic Sea Farms. Season 2 Episode 201 | 26m 4s Video has Closed Captions | CC. Atlantic Sea Farms partners with lobstermen up and down the rocky coast of Maine to farm kelp in the region's ...", "date": "2020-01-04", "full_content": "Atlantic Sea Farms\n\nSeason 2 Episode 201 | 26m 4sVideo hasClosed Captions|CC\n\nAtlantic Sea Farms partners with lobstermen on the rocky coast of Maine to farm kelp.\n\nAired 01/04/2020 | Expires 01/04/2028 | Rating TV-G\n\nSeason 2 Episode 201 | 26m 4sVideo hasClosed Captions|CC\n\nAtlantic Sea Farms partners with lobstermen on the rocky coast of Maine to farm kelp.\n\nAtlantic Sea Farms partners with lobstermen up and down the rocky coast of Maine to farm kelp in the region\u2019s icy waters. The cultivation of this fast-growing, highly nutritious sea vegetable is creating new economic opportunities for fisheries in Maine while also benefiting the ocean. Plus, it\u2019s delicious and chefs are finding creative ways to incorporate kelp into their menus.\n\nAired 01/04/2020 | Expires 01/04/2028 | Rating TV-G\n\nProblems playing video?Report a Problem|Closed Captioning Feedback\n\nBefore you submit an error, please consult ourVideo Help page.\n\nProblems playing video?Report a Problem|Closed Captioning Feedback\n\nBefore you submit an error, please consult ourVideo Help page.\n\ntasteMAKERSis presented by your local public television station.\n\ntasteMAKERS is made possible by our sponsors: Edward Jones, Fleischmann\u2019s Yeast, AB Mauri, and Natural Tableware. tasteMAKERS is distributed by American Public Television.\n\nSeason 2 Episode 201 | 26m 4sVideo hasClosed Captions|CC\n\nAtlantic Sea Farms partners with lobstermen up and down the rocky coast of Maine to farm kelp in the region\u2019s icy waters. The cultivation of this fast-growing, highly nutritious sea vegetable is creating new economic opportunities for fisheries in Maine while also benefiting the ocean. Plus, it\u2019s delicious and chefs are finding creative ways to incorporate kelp into their menus.\n\nAired 01/04/2020 | Expires 01/04/2028 | Rating TV-G\n\nProblems playing video?Report a Problem|Closed Captioning Feedback\n\nBefore you submit an error, please consult ourVideo Help page.\n\ntasteMAKERS\n\nS2Ep201\n\ntasteMAKERSis available to stream on pbs.org and the free PBS App, available on iPhone, Apple TV, Android TV, Android smartphones, Amazon Fire TV, Amazon Fire Tablet, Roku, Samsung Smart TV, and Vizio.\n\nProviding Support for PBS.org\n\nSupport for PBS provided by:\n\ntasteMAKERSis presented by your local public television station.\n\ntasteMAKERS is made possible by our sponsors: Edward Jones, Fleischmann\u2019s Yeast, AB Mauri, and Natural Tableware. tasteMAKERS is distributed by American Public Television.", "extraction_status": "cached"}, {"company": "Atlantic Sea Farms", "title": "Maine seaweed company bids for more growth, signs deal with business ...", "url": "https://www.pressherald.com/2022/10/03/maine-seaweed-company-looks-to-continue-expansion-with-new-investment-deal-with-top-chef-judge/", "source": "Portland Press Herald", "body": "Atlantic Sea Farms filed paperwork for the private financing with the Securities and Exchange Commission on Sept. 23. The funding drive comes a year after Atlantic raised $3.1 million in venture ...", "date": "2022-10-03", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nAtlantic Sea Farms filed paperwork for the private financing with the Securities and Exchange Commission on Sept. 23. The funding drive comes a year after Atlantic raised $3.1 million in venture ...", "extraction_status": "content_too_short"}, {"company": "VidaFuel", "title": "Vidafuel Nutrition Closes Oversubscribed $1.075 Million Financing to ...", "url": "https://www.digitaljournal.com/pr/4861343", "source": "Digital Journal", "body": "Vidafuel Nutrition Closes Oversubscribed $1.075 Million Financing to Advance its Clinical Nutrition Brand. By. GetNews. Published. October 30, 2020 ...", "date": "2020-10-30", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nVidafuel Nutrition Closes Oversubscribed $1.075 Million Financing to Advance its Clinical Nutrition Brand. By. GetNews. Published. October 30, 2020 ...", "extraction_status": "content_too_short"}, {"company": "VidaFuel", "title": "Jumpstart Foundry invests in Nashville startups VidaFuel and Well ...", "url": "https://www.bizjournals.com/nashville/news/2018/05/29/jumpstart-foundry-announces-2018-portfolio-brings.html", "source": "The Business Journals", "body": "VidaFuel. Eating healthy can be a challenge for anyone, but it can mean life or death for those with chronic disease. That's why Bette Parolini and Dr. Priyank Sharma created VidaFuel \u2014 a line ...", "date": "2018-05-29", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nVidaFuel. Eating healthy can be a challenge for anyone, but it can mean life or death for those with chronic disease. That's why Bette Parolini and Dr. Priyank Sharma created VidaFuel \u2014 a line ...", "extraction_status": "content_too_short"}, {"company": "Aloqia", "title": "Shein increases use of deadstock fabric by 40% in 2024 - MSN", "url": "https://www.msn.com/en-xl/news/other/shein-increases-use-of-deadstock-fabric-by-40-in-2024/ar-AA1CbCXN", "source": "MSN", "body": "Since 2022, Shein has sourced over 47,900 metres of deadstock fabric through Aloqia, leading to estimated savings of 357,600 cubic metres of water, 7,400 kilograms of chemicals, and 70 metric tons ...", "date": "2025-04-03", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nSince 2022, Shein has sourced over 47,900 metres of deadstock fabric through Aloqia, leading to estimated savings of 357,600 cubic metres of water, 7,400 kilograms of chemicals, and 70 metric tons ...", "extraction_status": "content_too_short"}, {"company": "Refiberd", "title": "eBay invests $300k in Refiberd to boost circular fashion with AI - MSN", "url": "https://www.msn.com/en-us/money/companies/ebay-invests-300k-in-refiberd-to-boost-circular-fashion-with-ai/ar-AA1CLdiz", "source": "MSN", "body": "US company Refiberd has secured a $300,000 investment from online marketplace eBay's venture capital arm to strengthen circular fashion efforts using a new AI system.", "date": "2025-04-11", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nUS company Refiberd has secured a $300,000 investment from online marketplace eBay's venture capital arm to strengthen circular fashion efforts using a new AI system.", "extraction_status": "content_too_short"}, {"company": "Refiberd", "title": "Refiberd Wins Trailblazer 2025 With AI-Powered Textile Recycling - MSN", "url": "https://www.msn.com/en-us/technology/tech-companies/refiberd-wins-trailblazer-2025-with-ai-powered-textile-recycling/ar-AA1GeqUb", "source": "MSN", "body": "Refiberd exemplifies how technological innovation can help bridge longstanding structural gaps in the fashion system,\" Federica Marchionni, CEO of the GFA, said.", "date": "2025-06-19", "full_content": "Note: Content could not be properly extracted from this source. Using summary instead.\n\nRefiberd exemplifies how technological innovation can help bridge longstanding structural gaps in the fashion system,\" Federica Marchionni, CEO of the GFA, said.", "extraction_status": "content_too_short"}, {"company": "Jiminy's", "title": "Jiminy's Is Fighting Climate Change One Pet Treat At A Time - Forbes", "url": "https://www.forbes.com/sites/davidriemer/2022/11/07/jiminys-is-fighting-climate-change-one-pet-treat-at-a-time/", "source": "Forbes", "body": "Jiminy's Chewy Cricket Treat. Jiminy's 2022. Carlson tells the story of Lauren, a millennial Jiminy's customer who refers to her dog Mordecai as \"her son.\"", "date": "2022-11-07", "full_content": "ByDavid Riemer,\n\nFormer Contributor.\n\nAnne Carlson, founder and CEO ofJiminy\u2019s, was two years into building her new, sustainable pet food company, before she was able to tell the story of why she created it. It turns out that the story was too emotional for Carlson to share in public. It was a classic \u201cpurpose story\u201d that began with an upsetting conversation Carlson had with her adult daughter about the future of our planet. The conversation was the \u201cinciting incident\u201d in her story that led the former Del Monte executive to tackle climate change by identifying new sources of protein for pet food\u2014starting with crickets. Since creating the company, Carlson and her team have raised $6 million in seed money, secured distribution in 1,100 Petco stores, built a direct-to-consumers business and generated millions in annual revenue. Now, as Carlson looks to raise a Series A to help dramatically scale the business, she has a new storytelling challenge.\n\nJiminy's CEO, Anne Carlson with her dogs Tuco (below) and Timber (above).\n\nBut this startup story starts with Carlson\u2019s origin story.\n\nWhile at Del Monte, Carlson helped aggregate and sell its pet food assets and rebrand them as Big Heart Pet Brands. In 2016, the J.M. Smucker Company bought the new pet brand, and Carlson moved on to think about her next thing. Around this time, Carlson had a conversation that most parents eventually have with their adult children about whether they hope to have kids one day. Carlson\u2019s daughter answered, \u201cno.\u201d She wouldn\u2019t want to bring them into a world that was devolving due to climate change. Carlson was heartbroken. She wished her daughter would experience the same joy she had raising a family. And she might have felt a bit guilty as well about not doing enough to change the narrative. Looking back, Carlson says, \u201cI realized that I couldn\u2019t just do a normal job after that\u2014building a better future for her was everything.\u201d\n\nBecause of Carlson\u2019s experience in the pet food business, she knew thatan estimated 25%-35%of domestic meat production was used to feed dogs and cats. Dogs alone consume 32 billion pounds of protein annually. The environmental impact of feeding pets in the U.S. is huge, because of the massive amount of land, water and feed required to raise cows and chickens. In researching alternatives, Carlson discovered that insects, especially crickets, are a tremendous source of protein that require a fraction of the resources required to produce traditional meat products. Cricket production, by example, generates 99% lessgreenhouse gasthan chicken production. Jiminy\u2019s was created to address this macro problem. In Carlson\u2019s early pitches, she focused on this big picture story.\n\nBut this is where things get more complicated and the real storytelling challenge emerges. The story that inspired Carlson to start the company is a memorable way to introduce Jiminy\u2019s, but to raise a series A, she must also convince investors that there\u2019s a massive market of pet owners willing to feed their dogs insect-based food. This is a common challenge for the founder who has a great origin story for their business. They\u2019ve told ustheirstory, but they\u2019ve yet to introduce the true protagonist in their product story. There has to be acustomerwith a set of needs that only Jiminy\u2019s can solve.\n\nThe good news for Carlson is that millennial and Gen Z pet owners are extraordinarily conscious of \u2014 and troubled by \u2014 the causes of climate change; and they\u2019re knowledgeable about emerging solutions. They also make-up nearly half the dog ownership in the U.S. Now Carlson has the protagonist for her new story.\n\nJiminy's Chewy Cricket Treat\n\nCarlson tells the story of Lauren, a millennial Jiminy\u2019s customer who refers to her dog Mordecai as \u201cher son.\u201d Lauren, like Carlson\u2019s daughter, is extremely worried about climate change so much so that she uses the \u201cgreener\u201d peer-to-peer videoconferencing solutionCrewdleinstead of Zoom for her work and non-profit board meetings. That\u2019s the big picture stuff. But when it comes to Mordecai, an adorable deaf rescue pup, Lauren\u2019s concerned about her dog\u2019s gut health. Mordecai isn\u2019t a lot of fun to be around, when suffering from stomach ailments. Lauren also wants meal options she can provide her pet throughout the day. Custom meal services are expensive and have way too much packaging. She\u2019d be delighted to try a more sustainable pet food, if it was healthy for the dog and came in different formats. Lauren\u2019s heard that insects are an emerging source of protein and she\u2019s willing to try something new.\n\nJiminy's expanding line-up of insect-based pet food.\n\nJiminy\u2019s answers the call. Jiminy\u2019s is asustainable pet foodusing insect protein. Once a customer like Lauren switches from a traditional meat-based pet food to Jiminy\u2019s, for example, it could save 200,000 to 2,000,000 gallons of water every year depending on the size of the dog and whether it had been eating chicken or beef based food (Jiminy\u2019s offers aneco-calculatorto figure this out). The food is nutritious, prebiotic and hypoallergenic. It includes fiber, iron, vitamin B2 and 12. And finally, Jiminy\u2019s offers a host of products from wet food to treats that can feed a dog throughout the day.\n\nFor her roadshow, Carlson will lead with her emotional origin story and quickly pivot to Lauren\u2019s story. Prospective investors will learn why Carlson is so passionate about creating a new pet brand to fight climate change, and why customers like Lauren are buying it. Lauren says, \u201csince switching (brands), Mordecai is a whole new dog. He's healthier, his fur is softer, his breath is better, and we can now breathe around him!\u201d And Lauren also feels like she\u2019s doing her part for the planet. It\u2019s a powerful one-two punch that Carlson hopes will help her raise an $8 million series A to expand her business and promote a healthier future one dog at a time.", "extraction_status": "cached"}, {"company": "Jiminy's", "title": "Don't Like Eating Insects? Your Pet Might.", "url": "https://www.nytimes.com/2025/07/03/science/pets-food-insects-lab-meat.html", "source": "The New York Times", "body": "Insects and lab-made animal protein have the potential to be far less damaging to the environment. And because pets tend to eat the same thing every day, changing their food \"can have real impact,\" Ms. Carlson said. \"It's like flipping a switch. One day it's unsustainable, the next, it's sustainable.\"", "date": "2025-07-03", "full_content": "Insect-protein entrepreneurs looking for open-minded eaters could hardly do better than a dog like Watson, who belongs to the author.Credit...\n\nSupported by\n\nByEmily Anthes\n\nEmily Anthes is a science reporter who writes Pet Theory, a column about our creature companions.\n\nIn an ideal world, Watson would have approached the treats cautiously, with a careful sniff and tentative lick. But, being a dog \u2014 with a voracious appetite and no discernible appreciation for narrative tension \u2014 he devoured them immediately. He didn\u2019t know, or care, that they were chock-full of dried crickets and ground-up grubs.\n\nAnd so what I had envisioned as a climactic taste test was over in seconds, with what was, in retrospect, an utterly predictable result: my dog would happily eat insects.\n\nFor years, some enterprising food entrepreneurs have been trying to convince people to do the same.As the global demand for protein grows, insects, they say, provide a more sustainable, ethical alternative to traditional meat. But the idea has been a tough sell. Although insects are a dietary staple in some cultures, for many people, they trigger a visceral disgust response.\n\nBut dogs? If they have a disgust reflex, I haven\u2019t seen it. Insect entrepreneurs looking for open-minded eaters could hardly do better than good old Canis lupus familiaris.\n\n\u201cThe dogs are not going to overthink it,\u201d said Anne Carlson, the chief executive of Jiminy\u2019s, which makes insect-based pet food and treats.\n\nHers is one of many pet food companies trying to remake meat. Earlier this year,the British company Meatlysold a limited run of dog treats made with lab-grown chicken. BioCraft Pet Nutrition, in Austria, is working to turn stem cells from mice into food for cats and dogs. And Bond Pet Foods, in the United States, is using yeast to produce animal protein through the process of fermentation.\n\nThere\u2019s still substantial skepticism about the future of insect protein and lab-grown meat in the human food supply \u2014 and about whether such ingredients can really wean us off our rib-eyes and fried chicken. Some entrepreneurs see pet food as a natural proving ground.\n\nIf a company can \u201ccrack the code for pet food, the path to commercialization could be relatively easier,\u201d said Rich Kelleman, the chief executive of Bond Pet Foods. Pet food companies don\u2019t need to replicate the experience of biting into a perfectly crisped drumstick. \u201cFor dogs and cats, it has to taste good,\u201d Mr. Kelleman said. \u201cBut it doesn\u2019t necessarily have to taste like chicken, exactly.\u201d\n\nIndustrial animal agriculture takes a profound toll on the environment, requiring lots of land and water, and producing significant pollution, including greenhouse gases.\n\nThe pet food industry, which often uses agricultural byproducts, has a smaller environmental footprint than the human food sector. \u201cBut it is material, and we shouldn\u2019t ignore it,\u201d said Peter Alexander, an expert on global food systems at the University of Edinburgh.\n\nIna 2020 study, Dr. Alexander and his colleagues found that dry dog and cat food accounted for between 1 and 3 percent of the greenhouse gas emissions associated with agriculture. (Wet food tends to contain more prime meat and have a higher impact.)\n\n\u201cFor individuals who maybe have a fairly low-emission diet and don\u2019t do much traveling, but they have a large dog \u2014 actually, the dog could have a really substantial footprint,\u201d Dr. Alexander said.\n\nInsects and lab-made animal protein have the potential to be far less damaging to the environment. And because pets tend to eat the same thing every day, changing their food \u201ccan have real impact,\u201d Ms. Carlson said. \u201cIt\u2019s like flipping a switch. One day it\u2019s unsustainable, the next, it\u2019s sustainable.\u201d\n\nReducing our reliance on industrial animal agriculture could also prevent immense animal suffering. \u201cIn the pet industry, it\u2019s all about loving animals,\u201d said Owen Ensor, the chief executive of Meatly. \u201cAnd I think a lot of people are increasingly uncomfortable with needing to harm and kill a lot of other animals to feed those animals.\u201d\n\nVegan pet food also addresses these problems but has to be very carefully formulated \u2014 and it won\u2019t appeal to all owners, alt-meat entrepreneurs say. \u201cPeople want to feed their pets meat,\u201d said Mr. Ensor, who is vegan but has two cats who are not.\n\nIn addition to Watson, I also have two cats. At first, figuring out how to feed them all was like trying to solve an impossible riddle.\n\nWatson, an intensely food-motivated dog with a heart condition, needs a weight-control kibble and must be kept away from the cat food, which he finds tantalizingly delicious. Juniper, my chronically underweight cat, should ideally have free access to her food \u2014 and is also a picky eater who reliably consumes only chicken. Then there\u2019s Goose, a cat who will eat until he makes himself sick and happens to have a food sensitivity to, yes, chicken.\n\nFinding the right meal plan for this menagerie took months of trial and error. So, as much as the sustainability and animal welfare arguments appeal to me, I\u2019m reluctant to start switching things up.\n\nI\u2019m not alone, apparently.\u201cWhat we\u2019re learning is that people don\u2019t really react or buy based on sustainability,\u201d Ms. Carlson said.\n\nShannon Falconer, the chief executive of BioCraft Pet Nutrition, agreed. \u201cThe main driver of any and all pet parent is the health of their animal,\u201d she said. \u201cThat will supersede anything else.\u201d In fact, another trend in the pet food market \u2014 the rise of high-end, human-grade products loaded with prime meat \u2014 runs directly counter to the quest for greater sustainability.\n\nSome companies are leaning hard into health claims. Insects, they say, are perfect for pets like Goose, who are sensitive or allergic to common proteins. It\u2019s a compelling argument, and if I ever need to find a new food for Goose, I\u2019d consider an insect-based one.\n\nBut I\u2019m not yet convinced by claims that insect protein is a \u201csuperfood\u201d \u2014 one that some companies suggest could improve everything from gut health and coat quality to cognition and immune function.\n\nResearch suggests that insects are indeed a \u201chigh-quality protein source,\u201d with good digestibility and palatability, said Kelly Swanson, a comparative nutritionist at the University of Illinois Urbana-Champaign. But data on specific functional benefits is limited, especially in cats and dogs. And companies will need to demonstrate that their products include enough of the ingredient to bring about whatever benefits they\u2019re promising, Dr. Swanson said.\n\nCreating nutritionally balanced products will require a deep understanding of these new proteins. Ina study published earlier this year, Belgian researchers found that many insect-based pet foods carried inaccurate nutritional labels, and that some of those products were deficient in one or more critical nutrients. \u201cThere are still a lot of gaps in the knowledge and research,\u201d said Camila Baptista da Silva, a doctoral student at Ghent University and an author of the study.\n\nFor their part, cultivated-meat companies note that their products are made without antibiotics or hormones, in controlled environments free of the pathogens that lurk in barns and slaughterhouses. But lab-grown meatisn\u2019t risk-free; it could contain novel allergens, or be contaminated by pathogens during the production process.\n\nUltimately, whether alternative proteins pay environmental dividends will depend on many factors, including how they are made \u2014 some production methods can be resource intensive \u2014 how widely they are adopted and what pet food products they displace.\n\nAs Dr. Alexander put it, \u201cIt all comes down to, \u2018What are you swapping from? What are you swapping to?\u2019\u201d Transitioning from pet food containing premium beef, which has an especially high environmental impact, to products with lab-grown meat would probably yield environmental benefits, he said. \u201cHowever, I\u2019m doubtful that switching from animal byproducts or plant-based ingredients to lab-grown meat will be beneficial,\u201d he added.\n\nAnd in order to have a real impact, alt-protein companies will need to produce these ingredients at higher quantities and lower prices. Meatly, which is currently raising money for an industrial-scale production facility, launched with a limited supply of dog treats made with just four percent cultivated chicken.\n\nYora Pet Foods sells large bags of its insect-based dog kibble for $4.50 to $5 a pound, more than one-and-a-half times what I pay for Watson\u2019s current food. At the moment, the grubs Yora uses cost almost as much to produce as free-range chicken, said James Milbourne, a managing director at the company. \u201cIf you walk into the shop and you\u2019ve got a bag of lovely free-range chicken and a bag of insects, and they\u2019re the same price,\u201d he said, \u201cit just makes it more difficult to get that person to take a punt on it.\u201d\n\nBut if companies can scale up and bring prices down, I do think customers will follow. Ina 2022 study, nearly half of dog and cat owners surveyed, including some who had no interest in eating lab-grown meat themselves, said they\u2019d be willing to feed cultivated meat to their pets.\n\nI\u2019d consider it, too, although there aren\u2019t currently such products available for purchase. And while I didn\u2019t want to change any of my pets\u2019 primary foods, I was happy to offer up some insect-based treats.\n\nGoose gobbled them down almost as quickly as Watson did. But fickle Juniper wouldn\u2019t touch the cricket treats, and she was hot and cold on the fly variety. Some days she seemed happy to scarf them down; other days she seemed almost offended by the offering. I could find no logic in her ever-shifting preferences. But there\u2019s no accounting for taste, I guess \u2014 or often, it seems, for cats.\n\nEmily Anthes is a science reporter, writing primarily about animal health and science. She also covered the coronavirus pandemic.\n\nAdvertisement", "extraction_status": "cached"}, {"company": "Aeromutable", "title": "No news", "url": "", "source": "", "body": "", "date": "2025-07-11", "full_content": "", "extraction_status": "not_attempted"}];
        const DEBUG = true;
    
        document.addEventListener('DOMContentLoaded', () => {
            const chatToggle = document.querySelector('.chat-toggle-button');
            const chatContainer = document.querySelector('.chatbot-container');
            const closeChat = document.querySelector('.close-chat');
            const chatInput = document.querySelector('.chatbot-input input');
            const sendButton = document.querySelector('.chatbot-input button');
            const messagesContainer = document.querySelector('.chatbot-messages');
            
            setTimeout(() => {
                chatContainer.classList.add('active');
                chatToggle.style.display = 'none';
                chatInput.focus();
            }, 1000);
            
            chatToggle.addEventListener('click', () => {
                chatContainer.classList.add('active');
                chatToggle.style.display = 'none';
                chatInput.focus();
            });
            
            closeChat.addEventListener('click', () => {
                chatContainer.classList.remove('active');
                setTimeout(() => {
                    chatToggle.style.display = 'flex';
                }, 300);
            });
            
            function sendMessage() {
                const question = chatInput.value.trim();
                if (!question) return;
                
                addMessage(question, 'user');
                chatInput.value = '';
                
                if (handleFollowUp(question)) {
                    return;
                }
                
                conversationState.currentQuery = question;
                conversationState.mode = 'showing_results';
                conversationState.currentArticleIndex = 0;
                processQuery(question);
            }
            
            function addMessage(text, sender) {
                const message = document.createElement('div');
                message.classList.add('message');
                message.classList.add(sender + '-message');
                message.textContent = text;
                messagesContainer.appendChild(message);
                messagesContainer.scrollTop = messagesContainer.scrollHeight;
            }
            
            function addMessageWithCitation(text, citation, url) {
                const messageContainer = document.createElement('div');
                
                const message = document.createElement('div');
                message.classList.add('message');
                message.classList.add('bot-message');
                message.textContent = text;
                
                // Create URL link element if URL is provided
                if (url && url !== "#") {
                    const linkElement = document.createElement('div');
                    linkElement.classList.add('source-link');
                    const link = document.createElement('a');
                    link.href = url;
                    link.target = "_blank"; // Open in new tab
                    link.textContent = url;
                    linkElement.appendChild(link);
                    messageContainer.appendChild(message);
                    messageContainer.appendChild(linkElement);
                } else {
                    // No URL, just add the message
                    messageContainer.appendChild(message);
                }
                
                messagesContainer.appendChild(messageContainer);
                messagesContainer.scrollTop = messagesContainer.scrollHeight;
            }
            
            function processQuery(question) {
                const lowerQuestion = question.toLowerCase();
                
                if (DEBUG) {
                    console.log('Processing query:', question);
                    console.log('Available articles:', newsData.length);
                }
                
                const isCompanyQuery = lowerQuestion.split(' ').length <= 3;
                
                if (isCompanyQuery) {
                    const allCompanies = [...new Set(newsData.map(article => article.company.toLowerCase()))];
                    console.log('All companies:', allCompanies);
                    
                    const exactCompanyMatch = allCompanies.find(company => 
                        company.toLowerCase() === lowerQuestion.trim()
                    );
                    
                    const validPartialMatch = allCompanies.some(company => {
                        const companyWords = company.toLowerCase().split(/\s+/);
                        const queryWords = lowerQuestion.toLowerCase().trim().split(/\s+/);
                        
                        if (company.toLowerCase() === lowerQuestion.toLowerCase().trim()) {
                            return true;
                        }
                        
                        if (company.toLowerCase().includes(lowerQuestion.toLowerCase().trim())) {
                            return true;
                        }
                        
                        if (lowerQuestion.toLowerCase().trim().includes(company.toLowerCase())) {
                            return true;
                        }
                        
                        if (companyWords.length > 1) {
                            if (queryWords.includes(companyWords[0]) && companyWords[0].length > 3) {
                                return true;
                            }
                            
                            const companyPhrase = companyWords.join(' ');
                            const queryPhrase = queryWords.join(' ');
                            
                            for (let i = 0; i < companyWords.length - 1; i++) {
                                const phrase = companyWords[i] + ' ' + companyWords[i+1];
                                if (queryPhrase.includes(phrase)) {
                                    return true;
                                }
                            }
                        }
                        
                        return false;
                    });
                    
                    const companyExists = exactCompanyMatch !== undefined || validPartialMatch;
                    
                    if (!companyExists) {
                        addMessage(`I'm sorry, I don't have any news articles about "${lowerQuestion}". Would you like information about another company?`, 'bot');
                        conversationState.mode = 'initial';
                        return;
                    }
                }
                
                let keywords = [];
                
                const quoteRegex = /"([^"]+)"/g;
                let quoteMatch;
                while ((quoteMatch = quoteRegex.exec(question)) !== null) {
                    keywords.push(quoteMatch[1].toLowerCase());
                }
                
                const stopWords = new Set([
                    'a', 'an', 'the', 'and', 'or', 'but', 'is', 'are', 'was', 'were', 
                    'to', 'of', 'in', 'on', 'at', 'by', 'for', 'with', 'about', 'from',
                    'these', 'those', 'this', 'that', 'have', 'has', 'had', 'do', 'does',
                    'did', 'can', 'could', 'will', 'would', 'should', 'may', 'might'
                ]);
                
                const wordKeywords = lowerQuestion
                    .replace(/[^a-zA-Z0-9 ]/g, ' ')
                    .split(' ')
                    .filter(word => word.length > 2 && !stopWords.has(word.toLowerCase()));
                    
                keywords = [...keywords, ...wordKeywords];
                
                if (DEBUG) {
                    console.log('Extracted keywords:', keywords);
                }
                
                let relevantArticles = [];
                newsData.forEach(article => {
                    let score = 0;
                    const title = article.title.toLowerCase();
                    const body = article.body.toLowerCase();
                    const fullContent = article.full_content ? article.full_content.toLowerCase() : '';
                    const company = article.company.toLowerCase();
                    
                    if (company && lowerQuestion.includes(company)) {
                        score += 15;
                    }
                    
                    if (company && lowerQuestion.trim() === company) {
                        score += 30;
                    }
                    
                    if (company && lowerQuestion.trim().startsWith(company)) {
                        score += 25;
                    }
                    if (company && company.startsWith(lowerQuestion.trim())) {
                        score += 20;
                    }
                    
                    if (isCompanyQuery && company && !company.includes(lowerQuestion) && !lowerQuestion.includes(company)) {
                        const companyFirstWord = company.split(' ')[0].toLowerCase();
                        const queryFirstWord = lowerQuestion.trim().split(' ')[0].toLowerCase();
                        
                        if (companyFirstWord !== queryFirstWord) {
                            score -= 50;
                        }
                    }
                    
                    if (fullContent && fullContent.includes(lowerQuestion)) {
                        score += 10;
                    }
                    
                    keywords.forEach(keyword => {
                        if (company && keyword.length > 2 && company === keyword) {
                            score += 18;
                        }
                        else if (company && keyword.length > 2 && company.includes(keyword)) {
                            score += 5;
                        }
                        if (company && keyword.length > 2 && keyword.includes(company)) {
                            score += 10;
                        }
                        
                        if (title.includes(keyword)) score += 5;
                        if (body.includes(keyword)) score += 3;
                        
                        if (fullContent) {
                            if (keyword.length > 10 && fullContent.includes(keyword)) {
                                score += 8;
                            } else if (fullContent.includes(keyword)) {
                                score += 2;
                            }
                            
                            const keywordRegex = new RegExp(keyword, 'gi');
                            const occurrences = (fullContent.match(keywordRegex) || []).length;
                            score += Math.min(occurrences, 5) * 0.5;
                        }
                    });
                    
                    if (lowerQuestion.includes('who') || lowerQuestion.includes('person')) {
                        const nameRegex = /([A-Z][a-z]+ [A-Z][a-z]+)/g;
                        const names = fullContent ? (fullContent.match(nameRegex) || []) : [];
                        if (names.length > 0) score += 2;
                    }
                    
                    if (score > 0) {
                        if (DEBUG) {
                            console.log(`Article: ${article.title}, Score: ${score}`);
                        }
                        relevantArticles.push({...article, score});
                    }
                });
                
                relevantArticles.sort((a, b) => b.score - a.score);
                
                conversationState.relevantArticles = relevantArticles;
                conversationState.currentArticleIndex = 0;
                
                if (DEBUG) {
                    console.log('Relevant articles found:', relevantArticles.length);
                    if (relevantArticles.length > 0) {
                        console.log('Top article:', relevantArticles[0].title);
                        console.log('Top score:', relevantArticles[0].score);
                    }
                }
                
                if (relevantArticles.length > 0) {
                    const mostRelevant = relevantArticles[0];
                    let response = "";
                    
                    let informativeSnippet = '';
                    if (mostRelevant.full_content) {
                        const fullContent = mostRelevant.full_content;
                        
                        const paragraphs = fullContent.split(/\n+/)
                            .filter(p => p.trim().length > 50);
                        
                        let foundRelevantSnippet = false;
                        for (const paragraph of paragraphs) {
                            const lowerPara = paragraph.toLowerCase();
                            const matchedKeywords = keywords.filter(kw => lowerPara.includes(kw));
                            
                            if (matchedKeywords.length >= 2) {
                                informativeSnippet = paragraph.trim().substring(0, 300) + '...';
                                foundRelevantSnippet = true;
                                break;
                            }
                        }
                        
                        if (!foundRelevantSnippet) {
                            for (const paragraph of paragraphs) {
                                if (keywords.some(keyword => paragraph.toLowerCase().includes(keyword))) {
                                    informativeSnippet = paragraph.trim().substring(0, 300);
                                    foundRelevantSnippet = true;
                                    break;
                                }
                            }
                        }
                        
                        if (!foundRelevantSnippet && fullContent.length > 0) {
                            if (fullContent.length > 500) {
                                const middleStart = Math.floor(fullContent.length / 3);
                                const middleContent = fullContent.substring(middleStart, middleStart + 500);
                                const sentences = middleContent.split(/[.!?] /).filter(s => s.length > 30);
                                
                                if (sentences.length > 0) {
                                    informativeSnippet = sentences[0].trim();
                                } else {
                                    informativeSnippet = fullContent.substring(0, 300);
                                }
                            } else {
                                informativeSnippet = fullContent.substring(0, 300);
                            }
                        }
                    }
                    
                    if (lowerQuestion.includes('what') && lowerQuestion.includes('company')) {
                        response = `${mostRelevant.company}: Based on the news, ${mostRelevant.company} has been mentioned in relation to: "${mostRelevant.title}"`;
                    } else if (lowerQuestion.includes('latest') || lowerQuestion.includes('recent')) {
                        response = `${mostRelevant.company}: The latest news I found is: "${mostRelevant.title}". ${mostRelevant.body.substring(0, 150)}`;
                    } else if (informativeSnippet) {
                        response = `${mostRelevant.company}: ${informativeSnippet}`;
                    } else {
                        response = `${mostRelevant.company}: ${mostRelevant.title} ${mostRelevant.body.substring(0, 150)}`;
                    }
                    
                    addMessageWithCitation(response, `${mostRelevant.source}`, mostRelevant.url);
                    
                    if (relevantArticles.length > 1) {
                        setTimeout(() => {
                            addMessage(`I also found ${relevantArticles.length - 1} more articles that might be relevant. Would you like to know more about any specific topic?`, 'bot');
                            conversationState.mode = 'offering_more';
                        }, 1000);
                    }
                } else {
                    addMessage(`I couldn't find any information about that in the current news articles. Could you try asking something else?`, 'bot');
                    conversationState.mode = 'initial';
                }
            }
            
            const conversationState = {
                mode: 'initial',
                currentQuery: '',
                relevantArticles: [],
                currentArticleIndex: 0
            };
            
            function handleFollowUp(response) {
                const lowerResponse = response.toLowerCase().trim();
                
                if (conversationState.mode === 'offering_more' && 
                    (lowerResponse === 'yes' || lowerResponse === 'sure' || 
                     lowerResponse === 'ok' || lowerResponse.includes('yes'))) {
                    
                    if (conversationState.relevantArticles.length > conversationState.currentArticleIndex + 1) {
                        conversationState.currentArticleIndex++;
                        const nextArticle = conversationState.relevantArticles[conversationState.currentArticleIndex];
                        
                        let response = '';
                        if (nextArticle.full_content) {
                            const snippet = nextArticle.full_content.substring(0, 300);
                            response = `${nextArticle.company}: ${snippet}`;
                        } else {
                            response = `${nextArticle.company}: ${nextArticle.title}. ${nextArticle.body.substring(0, 150)}`;
                        }
                        
                        addMessageWithCitation(response, `${nextArticle.source}`, nextArticle.url);
                        
                        const remaining = conversationState.relevantArticles.length - conversationState.currentArticleIndex - 1;
                        if (remaining > 0) {
                            setTimeout(() => {
                                addMessage(`I have ${remaining} more articles that might interest you. Would you like to see another one?`, 'bot');
                            }, 1000);
                        } else {
                            setTimeout(() => {
                                addMessage(`That's all the relevant articles I found. Is there something else you'd like to know about?`, 'bot');
                                conversationState.mode = 'initial';
                            }, 1000);
                        }
                        return true;
                    }
                }
                
                return false;
            }
            
            sendButton.addEventListener('click', sendMessage);
            chatInput.addEventListener('keypress', (e) => {
                if (e.key === 'Enter') sendMessage();
            });
            
            chatToggle.style.display = 'none';
            chatToggle.style.opacity = '1';
            
            setTimeout(() => {
                chatToggle.classList.add('attention');
            }, 2000);
        });
    
    </script>
</body>
</html>
